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Abstract 
Enantioselective reductive desymmetrization of glutarimides has been achieved employing an 
oxazaborolidine catalyst derived from cis-1-amino-indan-2-ol. The reaction was found to 
proceed through a stereoablative process that upgraded the enantioselectivity of an intermediate 
hydroxy-lactam. The reaction was generally tolerant of a number of substituents in the 4-
position, giving enantiomeric excesses of greater than 82%. 
Introduction 
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Desymmetrization to access chiral molecules is a popular strategy in organic synthesis, providing 
compounds with multiple stereogenic centers in one operation. The synthetic chemistry used in 
these strategies can be wide-ranging, for example, the addition of chiral alcohols to cyclic meso-
anhydrides to yield diastereomerically-enriched mono esters,1 or the use of chiral C3-symmetric 
zirconium(IV) and C2-symmetric chromium (III) complexes to catalyse the addition of azide 
nucleophiles to meso-epoxides.2 Desymmetrization of five-membered ring meso-imides is an 
important approach, as enantioselective reduction of one of the carbonyl groups leads to the 
chiral 5-hydroxy-2-pyrrolidinones, important intermediates in the synthesis of many natural 
products and other important heterocyclics.3±5 Strategies within this area of chemistry include the 
use of chiral auxiliaries,6 BINAL-H complexes,7 and thiazazincolidine complexes8 for 
enantioselective reduction to affect such transformations. Oxazaborolidine mediated borane 
reduction, using catalysts GHULYHGIURPĮĮ-diphenylprolinol have also been reported, but require 
as much as 50 mol% catalyst to obtain high yield and selectivity.9,10 Several reports from this 
research group have shown that alternative oxazaborolidine catalysts derived from cis-1-amino-
indan-2-ol are very effective for this desymmetrization process, proceeding with good 
enantiomeric excess at significantly lower catalyst loadings compared to reactions using the 
prolinol-derived catalyst,11 with further studies demonstrating the crucial role of the nitrogen 
substituent in obtaining high selectivities.12 The use of these catalysts for the kinetic resolution of 
racemic C-3 substituted imides has also been reported.13 More recently, in attempting to 
accessing the target molecule pyrrolam A, we have disclosed a hitherto unreported stereoablative 
process that serves to upgrade the enantioselectivity of this process.14 
Although there has been much work on the desymmetrisation of five-membered ring meso-
imides, the six-membered ring glutarimides have received little attention. There appear to be 
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only two strategies developed to desymmetrize glutarimides; the first by Simpkins and co-
workers using a chiral bis-lithium amide base to give chiral 3,4-disubstituted piperidin-2,5-
diones,15 and the second by Ikariya and co-workers using chiral Cp*Ru(PN) catalysts to affect 
the enantioselective hydrogenative desymmetrisation to give the corresponding hydroxyamides 
LQ H[FHOOHQW HH¶V -98%).16, 17 Here we present the enantioselective desymmetrisation of 3-
substituted glutarimides using oxazaborolidine catalysts derived from cis-1-amino-indan-2-ol.  
Results and discussion 
The 3-arylsubstituted glutaric acids 1b௅1f required for preparing the glutarimides, were 
synthesised from the corresponding aldehydes by adapting literature procedures. The aldehydes 
were first converted to the 2-substituted tetraethyl propane tetracarboxylates through 
Knoevenegel condensation followed by Michael addition.18 In the case of p-substituted aromatic 
aldehydes these solvent-free conditions do not give the required tetracarboxylates but instead 
yield the corresponding benzoic acid. However, drop-wise addition of a solution of the aldehyde 
in toluene to a mixture of diethylmalonate and AlCl3 in toluene in the Knoevenegel condensation 
step led to the required product. For the 3-alkyl glutaric acids 1h & 1i the method of Theisen et 
al. gave better yields which uses ethyl cyanoacetate in the Knoevenegel step and dimethyl 
sodiomalonate for the Michael addition (Scheme 1).19 The resultant dimalonates then underwent 
acid hydrolysis and decarboxylation giving the corresponding glutaric acids in moderate yields 
(Scheme 1). 3-Phenylglutaric acid 1a and 3-methylglutaric acid 1g are commercially available 
and were used as purchased. The glutarimides 3, 4a-i, 5 & 6 were accessed in a procedure 
developed by Ikariya et al. by transforming the glutaric acids 1a-i to the corresponding 
anhydrides 2a-i which were subsequently converted to the imides (Scheme 1, Table 1).16 
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Scheme 1. Route to glutarimide substrates 
Table 1. Synthesis of 3-Substituted Glutaric acids, Anhydrides, and Glutarimides 
   Yield 
Entry R1 R2 Glutaric acida Anhydride Imide 
1 Ph 4-MeOC6H4 1a b 2a 82% 3 80% 
2 Ph CH2C6H5 1a b 2a 82% 4a 85% 
3 Ph CH2(2-MeC6H4) 1a b 2a 82% 5 71% 
4 Ph CH2(2-MeOC6H4) 1a b 2a 82% 6 60% 
5 2-FC6H4 CH2C6H5 1b 52% 2b 75% 4b 87% 
6 4-FC6H4 CH2C6H5 1c 57% 2c 93% 4c 71% 
7 2-MeC6H4 CH2C6H5 1d 51% 2d 73% 4d 60% 
8 4-MeC6H4 CH2C6H5 1e 50% 3e 85% 4e 67% 
9 1-Naphthyl CH2C6H5 1f 60% 3f 80% 4f 52% 
10 Me CH2C6H5 1g b 3g 79% 4g 68% 
11 iPr CH2C6H5 1h 35% 3h 79% 4h 70% 
12 t-Bu CH2C6H5 1i 58% 3i 70% 4i 89% 
a
 Refers to yield of isolated product after 3 step sequence; b Commercially available material so no yield reported. 
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The initial screening for the best desymmetrization conditions was first carried out on N-PMP 
protected 3-phenylglutarimide 3 using both B-OMe catalyst 7 and B-Me catalyst 8 employing 
BH3.THF as borane source. Two methods of preparing the catalysts were evaluated; the first 
involved preparing the stock solution of the catalyst in situ at room temperature and using it 
immediately, while the second involved repeated azeotropic distillations before the final stock 
solution of the catalyst was made. In all cases, monitoring of the reaction by TLC indicated an 
optimum conversion to product after 3 h, and therefore the reactions were stopped at this point 
and the crude mixture reduced with triethylsilane to convert the intermediate hydroxyl-lactam to 
the more stable 2-piperidinone 10a to aid analysis (Scheme 2, Table 2). In all cases, the presence 
of the piperidine 11a was observed, formed by over-reduction of the intermediate hydroxy-
lactam. This relatively rapid formation of the doubly reduced product was observed in earlier 
work on related N-PMP five membered imides.14 
 
Scheme 2. Reduction of meso-glutarimides 3, 4a, 5 and 6. 
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Table 2. Screening Catalysts for Desymmetrisation of glutarimides 3, 4a, 5 and 6.a 
Entry Substrate Catalyst Method Product / yield (%) b 10a-d ee (%) c 
1 3 7 A d 3a (20) 10a (48) 11a (21) 99 
2 3 7 B e 3a (37) 10a (43) 11a (15) 99 
3 3 8 A d 3a (66) 10a (18) 11a (10) 53 
4 3 8 B e 3a (28) 10a (33) 11a (30) 95 
5 4a 7 A d 4a (60) 10b (34) 11b (5) 85 
6 4a 7 B e 4a (59) 10b (30) 11b (5) 92 
7 4a 8 A d 4a (62) 10b (20) 11b (9) 80 
8 4a 8 B e 4a (20) 10b (60) 11b (12) 90 
10 4a 9 B e ND f 10b (13) ND f 14 
11 5 8 B e ND f 10c (25) ND f 88 
12 6 8 B e ND f 10d (21) ND f 90 
a Reactions conducted by treating a solution of the glutarimide 3 in dry CH2Cl2 with 10 mol% of the catalyst solution 
and 1 equiv BH3.THF at rt for 3 h, followed work-up, dissolution into CH2Cl2 and treatment with Et3SiH / TFA for 1 
h. b Refers to isolated components after column chromatography. c Determined by chiral phase HPLC. d Catalyst 
prepared by mixing (1R, 2S)-cis-1-aminoindan-2-ol (1.00 mmol) and either trimethylborate (0.10 mL, 1.00 mmol) or 
trimethylboroxine (0.05 mL, 0.33 mmol) in THF (3 mL) and allowing to stir for 45 min, before dilution to 5 mL 
with THF. e Catalyst prepared by reaction of (1R, 2S)-cis-amino-2-indanol (1.00 mmol) in dry toluene (3 mL) with 
either trimethylboroxine (0.33 mmol) or trimethylborate (1.00 mmol) and allowed to stir for 30 min before 
azeotropic distillation with dry toluene. Dry dichloromethane (5 mL) was added to give a stock solution of the 
catalyst. f ND ± not determined. 
 
When using the N-PMP substrate 3 with the B-OMe catalyst, both methods of preparation gave 
excellent ee's of piperidinone 10a, however method A produced the 2-piperidinone 10a in a 48% 
yield and the undesired piperidine 11a in a 21% yield (Table 2, entry 1) while method B gave 
43% yield of the desired product 10a and 15% of the undesired product 11b (Table 2, entry 2). 
For the B-Me catalyst, a significant difference in both yield and enantioselectivity was observed 
for the two methods of preparing the catalyst (Table 2, entries 3 and 4). Only 18% yield and 53% 
ee of the desired product was obtained when the catalyst was prepared in situ at room 
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temperature while for the method involving azeotropic distillation gave 33% yield of the desired 
product in 95% ee. The undesired over-reduced product was also increased from 10% to 30%.  
The desymmetrisation of 3-phenyl N-benzyl glutarimide analogue 4a was also explored using 
both B-Me and B-OMe catalysts (Table 2, entries 5-8). The formation of the piperidine product 
11b was significantly slower compared to N-PMP glutarimide 3 which allowed the reaction time 
to be extended to as long as 24 hours. As expected, a slight decrease in selectivity was observed 
with both catalysts showing consistency with observations from earlier work on five-membered 
meso-imides.12 As with the PMP substrates, the B-OMe catalyst gave rather disappointing 
results, but again, use of the repetitive azeotropic distillation protocol for the preparation of B-
Me catalyst led to a significant increase in the yield of the desymmetrised product, from 33% 
(Table 2, entry 4) to 60% (Table 2, entry 8), with only a slight decrease in enantioselectivity. 
Thus, this was adopted as the optimum catalyst and procedure. For comparison purposes, 
desymmetrisation of N-benzyl-4-phenylpiperidin-2,5-dione 4a using these optimised conditions 
with a catalyst prepared in situ from (S)-(±)-ĮĮ-diphenyl-2-pyrrolidinemethanol 9 gave only 
13% yield and 14% ee of the lactam product 10b (Table 2, entry 10). This showed a remarkable 
superiority of oxazaborolidines derived from cis-1-amino-indan-2-ol over those derived from 
ĮĮ-diphenyl prolinol with these substrates. 
Since the change in nitrogen protecting group afforded a significant increase in yield, use of 
modified benzyl protecting groups (2-methylbenzyl and 2-methoxybenzyl) was probed, but this 
led to a significant fall in yield (25% and 21%, respectively) but kept the ee at excellent levels 
(Table 2, entries 11 & 12). This further reinforces the delicate nature of the N-protecting groups 
in influencing the yield and / or selectivity of the oxazaborolidine mediated desymmetrisation. 
Hence N-benzyl was chosen as the optimum protecting group for further exemplification.  
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Recently, we have reported the discovery of an in situ stereoablative process, partly responsible 
for the excellent ee observed for N-PMP anthracene-maleimide cyloadduct desymmetrisation.14 
This was also investigated in this series, with the B-Me catalyst 8, employing the repeated 
distillation procedure since the highest yield of the over-reduced compound with a significant 
change in selectivity was observed (Scheme 3). The N-PMP glutarimide substrate 3 was first 
reduced using both enantiomers of the B-Me catalyst 8 separately under standard conditions but 
purifying the intermediate hydroxy-lactams by flash column chromatography. This led to 
isolation of the two enantiomers of the hydroxy-lactam 12, both as a 2:1 diastereomeric ratio, in 
20% yield for (1R, 2S) catalyst and 27% yield for (1S, 2R) catalyst, respectively. A scalemic 
mixture of the two enantiomers of the hydroxy-lactam 12 was then prepared by mixing these in a 
2:1 ratio (1R, 2S:1S, 2R), and a portion of this quantitatively converted to the lactam to determine 
the ee. A sample of the scalemic hydroxyl-lactam mixture was then subjected to reduction with 
(1R, 2S) version of the B-Me catalyst followed by further reduction to the corresponding lactam. 
The same procedure was repeated with the (1S, 2R) version of the catalyst for comparison.  
 
Scheme 3. Stereoablation experiment with N-PMP glutarimide 3 
When a representative sample from the scalemic hydroxy-lactam 12 (31% ee) was subjected to 
reduction with (1R, 2S) enantiomer of the B-Me catalyst 8 followed by subsequent reduction 
with Et3SiH, the lactam was obtained in 73% yield and 60% ee. As observed in previous work 
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with the anthracene-maleimide, there was an upgrade in the ee of the scalemic hydroxy-lactam 
12 from 31% to 60%, showing a stereoablative reduction of one enantiomer of the hydroxy-
lactam by the (1R, 2S) catalyst (presumably the minor enantiomer) to the piperidine 11. On the 
other hand, when the reaction was repeated with (1S, 2R) version of the catalyst, a near identical 
yield of 75% of the lactam was obtained. However, unlike in the anthracene-maleimide case 
where the ee of the scalemic hydroxy-lactam remained the same with this version of the catalyst, 
the ee of the scalemic hydroxy-lactam in this case eroded to 14%. This shows that the (1S, 2R) 
catalyst selectively reduces the opposite enantiomer of the hydroxy-lactam, the major enantiomer 
in this case, thereby diminishing the ee of the scalemic hydroxy-lactam 12. Thus a double stereo-
differentiation process is operative whereby matched and mismatched catalyst / substrate 
combinations are observed with the two versions of the B-Me catalyst. The near identical yields 
of the lactam products obtained (73% & 75%) under the same experimental conditions suggests 
similar reaction rates of the two catalyst in this stereoablation reaction. Further experiments 
probing the effect of the nitrogen protecting group on the stereoablative process are underway. 
The optimum catalyst system (Table 2, entry 8) was then applied to the remainder of the N-
benzyl glutarimides 4b-i over a 24 hour period in an attempt to maximise yield and / selectivity. 
All 4-aryl substrates 4a-e furnished the chiral 2-piperidinones 13b(?i LQ PRGHUDWH \LHOGV (?
61%) and excellent enantioselHFWLYLWLHV RI (씀9 HH Scheme 4 and Table 3, entries 1(?4). 
However, a notable decrease in both yield and ee was observed when the aryl group was changed 
to 1-naphthyl (Table 3, entry 6). A change from 4-substituted aryls to 4-substituted alkyls 3g(?i 
was well tolerated but a slight drop in the yield of the products was noticeable (Table 3, entries 
6±8). As expected, residual starting material and over-reduced piperidine products were observed 
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in variable quantities in the 1H NMR spectrum of all unpurified reaction mixtures, but in these 
examples, only the 2-piperidinone was isolated and characterised. 
 
Scheme 4. Desymmetrisation of N-Bn glutarimides using B-Me catalyst 
Table 3. Desymmetrisation of N-benzyl-3-substituted glutarimides 4a-i using B-Me catalyst 8 a 
Entry Imide Product / yield (%) b ee (%) c Measured ሾȽሿୈଶ଴ Literature ሾȽሿୈଶ଴ 
1 4a 10b (60) 90 +33.0 (c 1.1, CHCl3) +35.0 (c 1.1, CHCl3)20 
2 4b 13b (61) 86 +39.4 (c 0.3, CHCl3) Unknown 
3 4c 13c (51) 88 + 33.6 (c 1.1, CHCl3) Unknown 
4 4d 13d (51) 82 + 20.1 (c 2.1, CHCl3) Unknown 
5 4e 13e (54) 92 +30.0 (c 1.1, CHCl3) +33.0 (c 1.1, CHCl3)20 
6 4f 13f (20) 54 -13.3 (c 0.5, CHCl3) Unknown 
7 4g 13g (46) 90 + 46.6 (c 3.3, CHCl3) Unknown 
8 4h 13h (41) 86 + 44.3 (c 1.9, CHCl3) Unknown 
9 4i 13i (46) 87 + 36.8 (c 1.4, CHCl3) Unknown 
a Reactions conducted by treating a solution of the glutarimide 4a-i in dry CH2Cl2 with 10 mol% of the catalyst 
solution [prepared by reaction of (1R, 2S)-cis-amino-indan-2-ol (1.00 mmol) in dry toluene (3 mL) with 
trimethylboroxine (0.33 mmol) and allowing to stir for 30 min before azeotropic distillation with dry toluene. Dry 
dichloromethane (5 mL) was added to give a stock solution of the catalyst] and 1 equiv BH3.THF at rt for 24 h, 
followed work-up, dissolution into CH2Cl2 and treatment with Et3SiH / TFA for 1 h. b Refers to isolated material 
after column chromatography. c Determined by chiral phase HPLC.  
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The absolute configuration was assigned as (4R) by comparison of the specific rotation with that 
of known compounds for the N-benzyl-4-phenyl lactam 10b (Table 3, entry 1) and N-benzyl-4-
(4-fluorophenyl) lactam 13e (Table 3, entry 5). The remainder of the N-benzyl products have 
comparable values to these, with the exception of the 1-naphthyl system (Table 3, entry 6) which 
has an outlying negative value (Table 6, entry 10). For the N-PMP-phenyl lactam 3, the specific 
rotation [+6.0 (c 1.3, CHCl3)] closely matched that of a related known compound, N-PMP-4-(4-
fluorophenyl)piperidin-2-one [+8.0 (c 1.3, CHCl3)21]. 
To explain the stereochemical outcome, two possible pre-transition state intermediates involving 
the imide and the borane-activated oxazaborolidine catalyst can be imagined (Figure 1). The 
models are based on the assumption that the catalyst is co-ordinated to the least hindered 
carbonyl lone pair anti to the amide C-N bond. When placing the borane B-H bond in the correct 
orientation to affect reduction of the carbonyl group, interactions of the B-Me bond occur with 
the group at the 4-position of the glutarimide.  
 
Figure 1. Pre-transition state models for imide reduction  
In conclusion, an efficient strategy for the highly enantioselective desymmetrisation of 
glutarimides using oxazaborolidines has been developed, providing an efficient method to access 
important piperidine building blocks. This strategy appears to be heavily reliant on catalysts 
derived from cis-1-amino-indan-2-ol. Further evidence has also been accrued for a stereoablative 
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upgrade of enantioselectivity through a double stereo-differentiation process with N-PMP-3-
phenyl glutarimide substrate, and more experiments probing this process are underway. 
 
Experimental Section 
General experimental methods 
All solvents were obtained dry from a dry solvent system and glassware was flame dried and 
cooled under vacuum before use. All dry reactions were carried out under a nitrogen atmosphere. 
TLC was carried out using aluminium TLC sheets (silica gel 60 F254), and was performed using a 
UV lamp or by dipping in KMnO4 solution then exposure to heat. Flash column chromatography 
was carried out with silica gel 40-63P 60Å. 1H and 13C NMR spectra were measured using 
CDCl3 as solvent unless otherwise stated. 13C NMR spectra were recorded using the JMOD 
method. Specific rotations were measured using the 589 nm (Na D-Line) at 20 oC unless 
otherwise stated, and are given in 10-1 deg cm2 g-1. HPLC was carried out using a Chiralcel (4.8 
mm × 250 mm) column with 10% or 20% iPrOH in hexane as the solvent. The flow rate was 
1.00 mL per minute and the detector was set at 220 nm or 254 nm. All chemicals were used as 
received without further purification except (1R,2S)-cis-1-amino-2-indanol and (1S,2R)-cis-1-
amino-2-indanol which were recrystallized from hot toluene prior to use. Borane-THF was used 
as a 1M solution in THF. 
General Procedure A for the synthesis of 3-(o-substituted phenyl) glutaric acids.18 
AlCl3 (0.1 equiv.) was slowly added to a mixture of 2-substituted benzaldehyde (1 equiv.) and 
diethylmalonate (2 equiv.) and stirred at room temperature for 24 hrs. The mixture was poured 
into an ice-water / conc. HCl solution mixture (25 : 5 mL) and extracted with CH2Cl2 (3 × 15 
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mL). The combined organic extracts were dried over MgSO4 and filtered. The solvent was 
removed in vacuo and excess diethylmalonate was removed by vacuum distillation (130 oC, 9.5 
× 10-1 mbar) to give the crude diethyl o-substituted benzylidenemalonate which was taken to 
next step without further purification. AlCl3 (0.05 equiv.) was slowly added to a mixture of the 
crude benzylidene malonate (1 equiv.) and diethylmalonate (1 equiv.) and stirred at 60 oC for 24 
h. Another portion of AlCl3 (0.05 equiv.) was slowly added to the mixture, the reaction 
temperature was raised to 70 oC and further stirred for additional 24 h. The mixture was allowed 
to cool to room temperature, poured into an ice / conc. HCl solution mixture (25 : 5 mL) and 
extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts were dried over MgSO4 and 
filtered. The solvent was removed in vacuo and excess diethylmalonate was removed by vacuum 
distillation (130 oC, 9.5 × 10-1 mbar) to give the crude material as an oily residue which was 
taken to the next synthetic step without further purification. This material was dissolved in conc. 
HCl (10 mL) was heated at reflux for 24 h. The conc. HCl was evaporated to about 4 mL and 
fresh conc. HCl (10 mL) was added and further heated at reflux for additional 24 h. The mixture 
was allowed to cool to room temperature, the solid was filtered and recrystallized from EtOAc / 
petroleum ether (40±60). 
General Procedure B for the synthesis of 3-(p-substituted phenyl) glutaric acids.18 
A solution of p-substituted benzaldehyde (1 equiv.) in toluene (10 mL) was added drop-wise to a 
mixture of AlCl3 (0.1 equiv.) and diethylmalonate (2 equiv.) in toluene (10 mL) and stirred at 
room temperature for 24 h. The mixture was poured into an ice-water / conc. HCl solution 
mixture (25 : 5 mL) and extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts were 
dried over MgSO4 and filtered. The solvent was removed in vacuo and excess diethylmalonate 
was removed by vacuum distillation (130 oC, 9.5 × 10-1 mbar) to give the crude diethyl p-
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substituted benzylidene malonate as oily residue which was taken to next step without further 
purification. AlCl3 (0.05 equiv.) was slowly added to a mixture of the crude benzylidene 
malonate (1 equiv.) and diethylmalonate (1 equiv.) and stirred at 60 oC for 24 h. Another portion 
of AlCl3 (0.05 equiv.) was slowly added to the mixture, the reaction temperature was raised to 70 
oC and further stirred for additional 24 h. The mixture was allowed to cool to room temperature, 
poured into an ice / conc. HCl solution mixture (25 : 5 mL) and extracted with CH2Cl2 (3 × 25 
mL). The combined organic extracts were dried over MgSO4 and filtered. The solvent was 
removed in vacuo and excess diethylmalonate was removed by vacuum distillation (130 oC, 9.5 
× 10-1 mbar) to leave the crude tetraethyl 2-(ortho or para substituted phenyl)propane-1,1,3,3-
tetracarboxylate as an oily residue which was taken to the next synthetic step without further 
purification. This material was dissolved in conc. HCl (10 mL) was heated at reflux for 24 h. The 
conc. HCl was evaporated to about 4 mL and fresh conc. HCl (10 mL) was added and further 
heated at reflux for additional 24 h. The mixture was allowed to cool to room temperature, the 
solid was filtered and recrystallized from EtOAc / petroleum ether (40±60). 
General Procedure C for the synthesis of 3-isopropyl & 3-tert-butyl glutaric acids 
A mixture of isobutyraldehyde or trimethylacetaldehyde (1.0 equiv.), ethylcyanoacetate (1.0 
equiv.) and piperidine (0.01 equiv.) in toluene (40 mL) was heated at reflux for 4 hours and 
allowed to cool to room temperature. The solvent was removed in vacuo and the residue was 
dissolved in CH2Cl2 (30 mL), dried over MgSO4 and filtered. The solvent was evaporated in 
vacuo to give an orange oily residue which was added to a solution of dimethylsodiomalonate 
[made from dimethylmalonate (1.0 equiv.) and sodium (0.1 equiv.) in dry MeOH (20 mL)]. The 
mixture was heated at reflux for 17 h, allowed to cool to room temperature and acidified with 1M 
HCl (15 mL). The mixture was then extracted with ether (5 × 60 mL) and the combined ethereal 
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fractions were washed with water (60 mL), dried over MgSO4 and filtered. The ether was 
evaporated under reduced pressure to give the crude cyanotricarboxylate as orange oil. The crude 
cyanotricarboxylate in conc. HCl (10 mL) was heated at reflux for 24 h. The conc. HCl was 
evaporated to about 4 mL and fresh conc. HCl (10 mL) was added. The reaction mixture was 
again heated at reflux for additional 24 h. The mixture was allowed to cool to room temperature, 
poured in to ice / water mixture (50 mL) and extracted with ether (5 × 30 mL). The combined 
ethereal portions were washed with water (20 mL), dried over MgSO4, filtered and solvent 
evaporated in vacuo to obtain a dark brown liquid which upon standing in fridge turned to brown 
solid, which was purified by recrystallisation from EtOAc / hexane. 
3-(2-Fluorophenyl)pentan-1,5-dioic acid 1b 
Using general procedure A starting with (8.250 g, 66.47 mmol) of 2-fluorobenzaldehyde and 
diethylmalonate (20.20 mL, 132.9 mmol), the crude diethyl 2-fluorobenzylidene malonate (17.00 
g) was obtained as a yellow liquid which was not purified [selected data: įH (400 MHz, CDCl3) 
1.26 (t, J = 6.6 Hz, 6H), 4.23 (qd, J = 7.1, 1.2 Hz, 4H(씀7m, 2H), 7.28(?7.34 (m, 1H), 
7.36±7.40 (m, 1H), 7.83 (s, 1H)]. This was taken onto the next step and the tetraethyl 2-(2-
fluorophenyl)propane-1,1,3,3-tetracarboxylate (23.29 g) was obtained as a yellow liquid. 
[selected data: įH (400 MHz, CDCl3) 0.90 (t, J = 7.1 Hz, 6H), 1.11 (t, J = 7.1 Hz, 6H), 3.82 (q, J 
= 7.1 Hz, 4H), 3.98±4.06 (m, 6H), 4.36 (t, J = 9.4 Hz, 1H), 6.83±6.88 (m, 1H), 6.90±6.94 (m, 
1H), 7.07±7.12 (m, 1H), 7.28±7.32 (m, 1H); įC (100 MHz, CDCl3) 13.7 (2 × CH3), 13.9 (2 × 
CH3), 38.3 (CH), 54.4 (2 × CH), 61.4 (2 × CH2), 61.7 (2 × CH2), 115.4 (d, JC-F = 22.9 Hz, CH), 
123.8 (d, JC-F = 3.3 Hz, CH), 124.8 (d, JC-F = 14.6 Hz, C), 129.5 (d, JC-F = 8.6 Hz, CH), 131.6 
(CH), 161.2 (d, JC-F = 248.0 Hz, C), 167.4 (2 × C), 167.8 (2 × C). Final decarboxylation gave a 
brown solid that was purified by recrystallization from EtOAc / petroleum ether (40±60) to give 
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the title compound 1b as white crystals (7.66 g, 52% over 3 steps); mp = 140±142 oC; Anal. 
Calcd for C11H11FO4: C, 58.41; H, 4.90. Found: C, 58.23; H, 4.96; Qmax /cm-1 (ATR) 2890 (brd, 
O-H), 1693 (s, C=O), 1489 (w, Ar C=C);  įH (400 MHz, DMSO) 2.58 (dd, J = 15.9, 8.5 Hz, 2H), 
2.66 (dd, J = 15.9, 6.6 Hz, 2H), 3.73 (quintet, J = 7.0 Hz, 1H), 7.09±7.15 (m, 2H), 7.21±7.27 (m, 
1H), 7.37 (td, J = 7.7, 1.5 Hz, 1H), 12.16 (s, 2H); įC (100 MHz, DMSO) 31.8 (CH), 39.4 (2 × 
CH2), 115.8 (d, JC-F = 22.5 Hz, CH), 124.7 (d, JC-F = 2.9 Hz, CH), 128.7 (d, JC-F = 8.4 Hz, CH), 
129.5 (d, JC-F = 4.5 Hz, CH), 130.4 (d, JC-F = 14.2 Hz, C), 160.7 (d, JC-F = 244.0 Hz, C), 173.1 (2 
× C); įF (235 MHz, DMSO) -117.9; MS (ESI+ TOF) m/z: 227 ([MH]+, 70%), 209 ([M - OH]+, 
100%).  
3-(4-Fluorophenyl)pentan-1,5-dioic acid 1c17 
Using general procedure B starting with (10.00 g, 80.57 mmol) of 4-fluorobenzaldehyde and 
diethylmalonate (24.50 mL, 161.1 mmol), the crude diethyl 4-fluorobenzylidenemalonate (18.22 
g) was obtained as a yellow liquid which was not purified {selected data; įH (400 MHz, CDCl3) 
0.90 (t, J = 7.1 Hz, 3H), 1.08 (t, J = 7.1 Hz, 3H), 4.16 (q, J = 7.1 Hz, 2H), 4.21 (q, J = 7.1 Hz, 
2H), 6.82 [(AX)2, 2H], 7.35 [(AX)2, 2H], 7.56 (s, 1H)}. This was taken onto the next step and the 
tetraethyl 2-(4-fluorophenyl)propane-1,1,3,3-tetracarboxylate (23.29 g) was obtained as a yellow 
liquid {selected data:  įH (400 MHz, CDCl3) 0.89 (t, J = 7.1 Hz, 6H), 1.08 (t, J = 7.1 Hz, 6H), 
3.82 (q, J = 7.1 Hz, 4H), 3.94±4.02 (m, 7H), 6.80 (app t, J = 8.7 Hz, 2H), 7.24 [(AX)2, 2H]}. 
Final decarboxylation gave a brown solid that was purified by recrystallization from EtOAc / 
petroleum ether (40±60) to give the title compound 1c as white crystals (9.881 g, 55% over 3 
steps); mp = 145±147 oC (lit.22 146±147 oC); Anal. Calcd for C11H11FO4: C, 58.41; H, 4.90. 
Found: C, 58.36; H, 4.65; ȣmax /cm-1 (ATR) 2914 (brd, O-H), 1708 (s, C=O), 1604 (w, Ar C=C), 
1509 (w, Ar C=C);  įH (400 MHz, DMSO) 2.51 (dd, J = 15.8, 8.8 Hz, 2H), 2.65 (dd, J = 15.8, 6.2 
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Hz, 2H), 3.37±3.45 (m, 1H), 7.10 [(AX)2, 2H], 7.31 [(AX)2, 2H], 12.11 (2brd s, 2H); įC (100 
MHz, DMSO) 37.7 (CH), 40.6 (2 × CH2), 115.3 (d, JC-F = 21.0 Hz, 2 × CH), 129.8 (d, JC-F = 7.8 
Hz, 2 × CH), 140.0 (d, JC-F = 2.6 Hz, C), 161.3 (d, JC-F = 242.0 Hz, C), 173.2 (2 × C); įF (235 
MHz, DMSO) -116.8; MS (ESI+ TOF) m/z: 250 ([MH + Na]+, 20%), 227 ([M + H]+, 30%), 209 
([M - OH]+, 100%). All data are in accordance with literature. 
3-(2-Methylphenyl)pentan-1,5-dioic acid 1d 
Using general procedure A starting with 2-methylbenzaldehyde (9.350 g, 77.82 mmol) and 
diethylmalonate (23.60 mL, 155.6 mmol), the crude diethyl 2-methylbenzylidene malonate 
(17.00 g) was obtained as a yellow liquid, which was not purified [selected data; įH (400 MHz, 
CDCl3) 1.05 (t, J = 7.1 Hz, 3H), 1.22 (t, J = 7.1 Hz, 3H), 2.24 (s, 3H), 4.10 (q, J = 7.1 Hz, 2H), 
4.20 (q, J = 7.1 Hz, 2H), 7.02±7.09 (m, 2H), 7.15 (app td, J = 7.5, 1.2 Hz, 1H), 7.26 (d, J = 7.5 
Hz, 1H), 7.87 (s, 1H)]. This was taken onto the next step and the crude tetraethyl 2-(2-
methylphenyl)propane-1,1,3,3-tetracarboxylate (15.90 g) was obtained as a yellow liquid 
[selected data;  įH (400 MHz, CDCl3) 0.89 (t, J = 7.1 Hz, 6H), 1.17 (t, J = 7.1 Hz, 6H), 2.42 (s, 
3H), 3.80 (q, J = 7.1 Hz, 4H), 3.96 (d, J = 9.5 Hz, 2H), 4.03±4.11 (m, 4H), 4.51 (t, J = 9.5 Hz, 
1H), 7.00±7.06 (m, 3H), 7.18 (d, J = 6.8 Hz, 1H)]. Final decarboxylation gave a brown solid that 
was purified by recrystallization from EtOAc / petroleum ether (40±60) giving the title 
compound 1d as white crystals (8.942 g, 52% over 3 steps); mp = 154±156 oC; Anal. Calcd for 
C12H14O4: C, 64.85; H, 6.35. Found: C, 64.71; H, 6.46; ȣmax /cm-1 (ATR) 2971 (brd, O-H), 1708 
(,s C=O) 1514 (w, Ar C=C); įH (400 MHz, DMSO) 2.37 (s, 3H), 2.49±2.63 (m, 4H), 3.69±3.76 
(m, 1H), 7.04±7.16 (m, 3H), 7.27 (d, J = 7.6 Hz, 1H), 12.60 (s, 2H); įC (100 MHz, DMSO) 19.7 
(CH3), 33.2 (CH), 40.5 (2 × CH2), 126.2 (CH), 126.4 (CH), 126.5 (CH), 130.5 (CH), 136.2 (C), 
142.3 (C), 173.4 (2 × C); MS (ESI- TOF) m/z: 221 ([M-H]-, 100%). 
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3-(4-Methylphenyl)pentan-1,5-dioic acid 1e23 
Using general procedure B starting with 4-methylbenzaldehyde (10.00 g, 83.23 mmol) and 
diethylmalonate (25.30 mL, 166.5 mmol), the crude diethyl 4-methylbenzylidenemalonate (17.23 
g) was obtained as a yellow liquid, which was not purified [selected data; įH (400 MHz, CDCl3) 
1.20 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 7.1 Hz, 3H), 2.24 (s, 3H), 4.18 (q, J = 7.2 Hz, 2H), 4.24 (q, J 
= 7.1 Hz, 2H), 7.07 (d, J = 8.1 Hz, 1H), 7.25 (d, J = 8.1 Hz, 1H), 7.60 (s, 1H)]. This was taken 
onto the next step and the crude tetraethyl 2-(4-methylphenyl)propane-1,1,3,3-tetracarboxylate 
(25.20 g) was obtained as a yellow liquid [selected data;  įH (400 MHz, CDCl3) 0.98 (t, J = 7.1 
Hz, 6H), 1.18 (t, J = 7.1 Hz, 6H), 2.22 (s, 3H), 3.90 (q, J = 7.1 Hz, 4H), 4.02±4.15 (m, 7H), 7.00 
(d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H)]. Final decarboxylation gave a brown solid that was 
purified by recrystallization from EtOAc / petroleum ether (40±60) to give the title compound 1e 
as white crystals (10.55 g, 57% over 3 steps); mp = 122±124 oC (lit.23 118(?121 oC); Anal. Calcd 
for C12H14O4: C, 64.85; H, 6.35. Found: C, 64.85; H, 6.13; ȣmax /cm-1 (ATR) 2925 (brd, O-H), 
1704 (s, C=O), 1515 (w, Ar C=C);  įH (400 MHz, DMSO) 2.25 (s, 3H), 2.48 (dd, J = 15.7, 8.7 
Hz, 2H), 2.62 (dd, J = 15.7, 6.3 Hz, 2H), 3.34±3.41 (m, 1H), 7.07 (d, J = 8.0 Hz, 2H), 7.14 (d, J 
= 8.0 Hz, 2H), 12.06 (s, 2H); įC (100 MHz, DMSO) 21.1 (CH3), 38.0 (CH), 40.7 (2 × CH2), 
127.8 (2 × CH), 129.2 (2 × CH), 135.8 (C), 140.8 (C), 173.3 (2 × C); MS (ESI+ TOF) m/z: 223 
([MH]+, 10%), 205 ([M - OH]+, 100%). Literature 13C NMR data is missing a signal at 40.7 
otherwise all data are in accordance with literature. 
3-(1-Naphthyl)pentan-1,5-dioic acid 1f24 
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Using general procedure A starting with 1-naphthaldehyde (10.35 g, 66.27 mmol) and 
diethylmalonate (20.12 mL, 132.5 mmol), the crude diethyl 1-naphthylidenemalonate (19.25 g) 
was obtained as a pale yellow liquid, which was not purified [selected data; įH (400 MHz, 
CDCl3) 1.06 (t, J = 7.1 Hz, 3H), 1.38 (t, J = 7.1 Hz, 3H), 4.18 (q, J = 7.1 Hz, 2H), 4.38 (q, J = 
7.1 Hz, 2H), 7.42 (t, J = 7.8 Hz, 1H), 7.49±7.56 (m, 2H), 7.61 (d, J = 7.8 Hz, 1H), 7.83±7.87 (m, 
2H), 8.00 (d, J = 7.8 Hz, 1H), 8.50 (s, 1H)]; This was taken onto the next step and the crude 
tetraethyl 2-(1-naphthyl)propane-1,1,3,3-tetracarboxylate (32.56 g) was obtained as dark brown 
liquid [selected data;  įH (400 MHz, CDCl3) 0.73 (t, J = 7.1 Hz, 6H), 1.17 (t, J = 7.1 Hz, 6H), 
3.67±3.76 (m, 4H), 4.06±4.14 (m, 4H), 4.24 (d, J = 9.0 Hz, 2H), 5.25 (t, J = 9.0 Hz, 1H), 7.37 (t, 
J = 7.7 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.51±7.56 (m, 2H), 7.70 (d, J = 8.1 Hz, 1H), 7.76 (d, J 
= 8.1 Hz, 1H), 8.41 (d, J = 8.1 Hz, 1H)]; )]. Final decarboxylation gave a brown solid that was 
purified by recrystallization from EtOAc / petroleum ether (40±60) giving the title compound 1f 
as white crystals (10.20 g, 60% over 3 steps); mp =185±187 oC (lit.24 181.5 oC); Anal. Calcd for 
C15H14O4: C, 69.76; H, 5.46. Found: C, 69.64; H, 5.39; ȣmax /cm-1 (ATR) 2904 (brd, O-H), 1707 
(s, C=O), 1599 (w, C=C), 1511 (w, C=C); įH (400 MHz, DMSO) 2.76 (d, J = 7.2 Hz, 4H), 3.39 
(quintet, J = 7.2 Hz, 1H), 7.46±7.62 (m, 4H), 7.80 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 
8.21 (d, J = 8.6 Hz, 1H), 12.17 (s, 2H); įC (100 MHz, DMSO) 38.0 (CH), 40.3 (2 × CH2), 123.5 
(CH), 123.7 (CH), 125.9 (CH), 126.0 (CH), 126.6 (CH), 127.3 (CH), 129.2 (CH), 131.5 (C), 
134.0 (C), 140.0 (C), 173.4 (2 × C); MS (ESI- TOF) m/z: 257 ([M-H]-, 100%). Only melting 
point is reported in the literature. 
3-Isopropylpentan-1,5-dioic acid 1h25 
Using general procedure C starting with isobutyraldehyde (10.00 g, 138.7 mmol), the title 
compound 1h was obtained as white crystals by recrystallization from EtOAc / petroleum ether 
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(40±60) (8.211 g, 34% over 3 steps); mp = 94±96 oC (lit.25 87.5±88.5 oC); Anal. Calcd for 
C8H14O4: C, 55.16; H, 8.10. Found: C, 55.14; H, 8.16; ȣmax /cm-1 (ATR) 2966 (brd, O-H), 1692 
(s, C=O); įH (400 MHz, DMSO) 0.82 (d, J = 6.9 Hz, 6H), 1.70 (pent d, J = 6.9, 3.4 Hz, 1H), 
2.10±2.15 (m, 3H), 2.19±2.26 (m, 2H), 12.10 (brd s, 2H); įC (100 MHz, DMSO) 19.2 (2 × CH3), 
29.9 (CH), 35.9 (2 × CH2), 37.5 (CH), 174.5 (2 × C); MS (ESI+ TOF) m/z: 198 ([M + Na]+, 
40%), 175 ([MH]+, 30%), 157 ([M-OH]+, 100%). Only melting point is given in literature. 
3-tert-Butylpentan-1,5-dioic acid 1i26 
Using general procedure C starting with trimethylacetaldehyde (10.00 g, 116.3 mmol), the title 
compound 1i was obtained as white crystals by recrystallization from EtOAc / petroleum ether 
(40±60) (12.76 g, 58% over 3 steps); mp = 146±148 oC (lit.26 153±154 o& ȣmax (ATR)/cm-1 
2966 (brd, O-H), 1704 (s, C=O); įH (400 MHz, CDCl3) 0.96 (s, 9H), 2.15±2.22 (m, 2H), 2.32 (tt, 
J = 9.7, 1.8 Hz, 1H), 2.66 (dd, J = 14.2, 1.8 Hz, 2H), 12.36 (brd s, 2H); įC (100 MHz, CDCl3) 
27.3 (3 × CH3), 33.1 (C), 36.1 (2 × CH2), 42.4 (CH), 180.9 (2 × C); MS (ESI+TOF) m/z: 230 
([MH+Na]+, 30%), 212 ([MH]+, 55%), 189 ([M-OH]+, 100%), 171 (70%); HRMS (ESI+TOF): 
calcd for C9H17O4 ([MH]+), 1891127; found, 189.1130. Only melting point and 1H NMR were 
reported in the literature.  
General Procedure D for the synthesis of glutaric anhydrides.16  
A mixture of glutaric acid in acetyl chloride (30 mL) was heated at reflux for 48 h. The mixture 
was cooled to room temperature and the acetyl chloride was removed in vacuo to give brown 
liquid which was purified by recrystallisation. 
4-Phenyldihydropyran-2,6-dione 2a19 
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Using general procedure D starting with commercially available 3-phenylglutaric acid (4.10 g, 
0.02 mol), the title compound 2a was obtained as white crystals by recrystallization from EtOAc 
/ hexane (3.22 g, 84%); mp = 104±106 oC (lit.19 104±105 oCȣmax /cm-1 (ATR) 1812 (s, C=O), 
1752 (s, C=O); įH (400 MHz, CDCl3) 2.90 (dd, J = 17.5, 11.5 Hz, 2H), 3.11 (dd, J = 17.5, 4.3 
Hz, 2H), 3.42 (tt, J = 11.5, 4.3 Hz, 1H), 7.21±7.24 (m, 2H), 7.34±7.45 (m, 3H); įC (100 MHz, 
CDCl3) 34.1 (CH), 37.2 (2 × CH2), 126.2 (2 × CH), 128.2 (CH), 129.4 (2 × CH), 139.1 (C), 
165.8 (C); MS (ESI+TOF) m/z: 191 ([MH]+, 100%),. All data in accordance with the literature.  
4-(2-Fluorophenyl)dihydropyran-2,6-dione 2b 
Using general procedure D starting with glutaric acid 1b (3.00 g, 13.3 mmol), the title compound 
2b was obtained as white crystals by recrystallization from EtOAc / petroleum ether (40±60) 
(2.00 g, 73%); mp 84±86 o&ȣmax /cm-1 (ATR) 1812 (w), 1754 (s, C=O), 1710 (s, C=O), 1586 
(w, C=C);  įH (400 MHz, CDCl3) 2.99 (dd, J = 17.2, 11.2 Hz, 2H), 3.13 (dd, J = 17.2, 4.2 Hz, 
2H), 3.66(?3.73 (m, 1H), 7.11±7.21 (m, 3H), 7.33±7.38 (m, 1H); įC (100 MHz, CDCl3) 28.9 
(CH), 35.5 (2 × CH2), 116.3 (d, JC-F = 21.8 Hz, CH), 125.0 (d, JC-F = 3.4 Hz, CH), 126.0 (d, JC-F 
= 13.3 Hz, C), 127.2 (d, JC-F = 3.8 Hz, CH), 129.9 (d, JC-F = 8.5 Hz, CH), 160.7 (d, JC-F = 246.6 
Hz, C), 165.7 (2 × C); įF (235 MHz, CDCl3) -117.0; MS (EI+) m/z: 208 ([M]+, 30%), 122 
(100%), 96 (20%); HRMS (EI+): calcd for C11H9FO3 ([M]+), 208.0536; found, 208.0544. 
4-(4-Fluorophenyl)dihydropyran-2,6-dione 2c27 
Using general procedure D starting with glutaric acid 1c (2.50 g, 11.1 mmol), the title compound 
2c was obtained as white crystals by recrystallization from EtOAc / petroleum ether (40±60) 
(1.96 g, 85%); mp = 84 ± 86 oC (lit.27 98 oC); Anal. Calcd for C11H9FO3: C, 63.46; H, 4.36. 
Found: C, 63.22; H, 4.08; ȣmax /cm-1 (ATR) 1806 (s, C=O), 1755 (s, C=O), 1717 (m, C=O), 1606 
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(w, C=C), 1512 (s, C=C);  įH (400 MHz, CDCl3) 2.86 (dd, J = 17.4, 11.4 Hz, 2H), 3.13 (dd, J = 
17.4, 4.4 Hz, 2H), 3.45 (tt, J = 11.4, 4.4 Hz, 1H), 7.09±7.14 (m, 2H), 7.18±7.23 (m, 2H); įC (100 
MHz, CDCl3) 33.5 (CH), 37.3 (2 × CH2), 116.4 (d, JC-F = 21.6 Hz, 2 × CH), 127.9 (d, JC-F = 8.1 
Hz, 2 × CH), 134.8 (d, JC-F = 3.2 Hz, C), 162.3 (d, JC-F = 248.5 Hz, C), 165.6 (2 × C); MS (EI+) 
m/z: 208 ([M]+, 40%), 123 (30%), 122 (100%). All data are in accordance with literature.  
4-(2-Methylphenyl)dihydropyran-2,6-dione 2d28 
Using general procedure D starting with glutaric acid 1d (3.00 g, 13.5 mmol), the title compound 
2d was obtained as white crystals by recrystallization from EtOAc / hexane (2.07 g, 75%); mp = 
103±105 oC (lit.28 106±109 o&ȣmax (ATR)/cm-1 1808 (s, C=O), 1749 (s, C=O), 1712 (s, C=O);  
įH (400 MHz, CDCl3) 2.39 (s, 3H), 2.86 (dd, J = 17.4, 11.6 Hz, 2H), 3.08 (dd, J = 17.4, 4.4 Hz, 
2H), 3.65 (tt, J = 11.6, 4.4 Hz, 1H), 7.13 (d, J = 6.9 Hz, 1H), 7.24±7.31 (m, 3H); įC (100 MHz, 
CDCl3) 19.3 (CH3), 30.1 (CH), 36.6 (2 × CH2), 124.1 (CH), 127.1 (CH), 127.9 (CH), 131.4 
(CH), 135.6 (C), 137.2 (C), 166.1 (2 × C); MS (EI+) m/z: 204 ([MH]+, 40%), 144 (60%), 118 
(100%), 91 (45%); HRMS (EI+): calcd for C12H12O3 ([MH]+), 204.0786; found, 204.0792. All 
data are in accordance with literature. 
4-(4-Methylphenyl)dihydropyran-2,6-dione 2e29 
Using general procedure D starting with glutaric acid 1e (7.00 g, 31.5 mmol), the title compound 
2e was obtained as white crystals by recrystallization from EtOAc / petroleum ether (40±60) 
(6.00 g, 93%); mp = 136±138 o& ȣmax /cm-1 (ATR) 1806 (s, C=O), 1753 (s, C=O), 1518 (w, 
C=C); įH (400 MHz, CDCl3) 2.37 (s, 3H), 2.87 (dd, J = 17.4, 11.4 Hz, 2H), 3.12 (dd, J = 17.4, 
4.5 Hz, 2H), 3.41 (tt, J = 11.4, 4.5 Hz, 1H), 7.11 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 8.0 Hz, 2H); įC 
(100 MHz, CDCl3) 21.0 (CH3), 33.7 (CH), 37.3 (2 × CH2), 126.1 (2 × CH), 130.0 (2 × CH), 
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136.1 (C), 138.0 (C), 165.9 (2 × C); MS (EI+) m/z: 204 ([M]+, 40%), 118 (100%), 91 (20%); 
HRMS (EI+): calcd for C12H12O3 ([M]+), 204.0786; found, 204.0796. No analytical data was 
given for the compound in the literature.  
4-(1-Naphthyl)dihydropyran-2,6-dione 2f 
Using general procedure D starting with glutaric acid 1f (3.00 g, 0.01 mol), the title compound 2f 
was obtained as white crystals by recrystallization from EtOAc / petroleum ether (40±60) (2.24 
g, 80%); mp = 148±150 oC; Anal. Calcd for C15H12O3: C, 74.99; H, 5.03. Found: C, 74.64; H, 
4.68; ȣmax /cm-1 (ATR) 1808 (s, C=O), 1753 (s, C=O), 1599 (w, C=C);  įH (400 MHz, CDCl3) 
3.05 (dd, J = 17.3, 10.5 Hz, 2H), 3.31 (dd, J = 17.3, 4.5 Hz, 2H), 4.28 (tt, J = 10.5, 4.5 Hz, 1H), 
7.31 (d, J = 7.2 Hz, 1H), 7.49(?7.53 (m, 1H), 7.57±7.66 (m, 2H), 7.87 (d, J = 8.2 Hz, 1H(?
7.98 (m, 2H); įC (100 MHz, CDCl3) 29.5 (CH), 36.8 (2 × CH2), 121.8 (CH), 122.0 (CH), 125.5 
(CH), 126.3 (CH), 127.1 (CH), 128.9 (CH), 129.5 (CH), 130.6 (C), 134.1 (C), 134.8 (C), 166.0 
(2 × C); MS (TOF MS ES+) m/z: 241 ([MH]+, 100%). 
4-Methyldihydropyran-2,6-dione 2g30 
Using general procedure D starting with commercially available 3-methylglutaric acid (10.0 g, 
63.5 mmol), the title compound 2g was obtained as white crystals by recrystallization from 
EtOAc / petroleum ether (40±60) (6.89 g, 79%); mp = 44±46 oC (lit.30 45±46 oC); Anal. Calcd 
for C6H8O3: C, 56.24; H, 6.29. Found: C, 56.27; H, 6.31; ȣmax /cm-1 (ATR) 2977 (w, C-H), 1806 
(s, C=O), 1757 (s, C=O), 1744 (s, C=O);  įH (400 MHz, CDCl3) 1.16 (d, J = 6.4 Hz, 3H), 2.29±
2.37 (m, 1H), 2.39±2.46 (m, 2H), 2.88 (dd, J = 17.1, 4.2 Hz, 2H); įC (100 MHz, CDCl3) 20.0 
(CH3), 24.0 (CH), 37.7 (2 × CH2), 166.4 (2 × C); MS (TOF MS ES+) m/z: 129 ([MH]+, 100%). 
Only a melting point and a copy of the 1H NMR spectrum are recorded in the literature. 
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4-Isopropyldihydropyran-2,6-dione 2h19 
Using general procedure D starting with glutaric acid 1h (5.74 g, 33.0 mmol), a brown liquid was 
obtained. This was vacuum distilled (bp = 110 oC, 85 × 10-2 mbar, lit.19 138 oC, 0.5 Torr) to give 
a colourless liquid which solidified upon standing. This was recrystallized from hexane to give 
the title compound 2h as white crystals (3.93 g, 76%); mp = 25±26 oC (lit.19 25.5±26.5 o&ȣmax 
/cm-1 (ATR) 2967 (m, C-H), 2878 (m, C-H), 1798 (s, C=O), 1757 (s, C=O), 1702 (s, C=O); įH 
(400 MHz, CDCl3) 0.97 (d, J = 6.8 Hz, 6H), 1.62 (octet, J = 6.8 Hz, 1H), 1.94 (dtt, J = 6.8, 11.5, 
4.4 Hz, 1H), 2.43 (dd, J = 17.3, 11.5 Hz, 2H), 2.88 (dd, J = 17.3, 4.4 Hz, 2H); įC (100 MHz, 
CDCl3) 18.9 (2 × CH3), 31.3 (CH), 34.0 (2 × CH2), 35.0 (CH), 166.9 (2 × C); HRMS (ESI+TOF): 
calcd for C8H13O3 ([MH]+), 157.0865; found, 157.0870. All data are in accordance with 
literature. 
4-tert-Butyldihydropyran-2,6-dione 2i19 
Using general procedure D starting with glutaric acid 1i (5.00 g, 26.6 mmol), a brown liquid was 
obtained that was vacuum distilled (bp = 120 oC, 16 × 10-2 mbar, lit.19 146±148 oC, 0.5 Torr), to 
give a colourless liquid which solidified upon standing to give the title compound 2i as a white 
solid (3.15 g, 70%); mp = 62±64 oC (lit.19 63.5±64.5 o&ȣmax /cm-1 (ATR) 2967 (m, C-H), 1808 
(s, C=O), 1748 (s, C=O); įH (400 MHz, CDCl3) 0.96 (s, 9H), 1.94 (tt, J = 12.9, 4.1 Hz, 1H), 
2.35(?2.43 (m, 2H), 2.90 (dd, J = 17.2, 4.1 Hz, 2H); įC (100 MHz, CDCl3) 26.4 (3 × CH3), 32.0 
(C), 32.3 (2 × CH2), 38.7 (CH), 167.2 (C); HRMS (ESI+TOF): calcd for C9H15O3 ([MH]+), 
171.1021; found, 171.1024. All data are in accordance with literature. 
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General Procedure E for the synthesis of glutarimides.16 
The corresponding amine (1.0 equiv) was slowly added to a solution of the glutaric anhydride 
(1.0 equiv) and triethylamine (1.0 equiv) in dry THF (30 mL). The mixture was heated at reflux 
for 48 h, cooled to room temperature and concentrated under reduced pressure. Dichloromethane 
(15 mL) was added and the resulting solution was washed with 1M HCl (5 mL) and brine (5 
mL), dried over MgSO4 and filtered. The solvent was removed in vacuo and the residue was 
dissolved in acetyl chloride (30 mL), heated at 60 oC for 48 h and cooled to room temperature. 
The solvent was removed in vacuo to give a brown solid which was purified by recrystallization. 
N-(4-Methoxyphenyl)-4-phenylpiperidin-2,6-dione 3 
Using general procedure E starting with 3-phenylglutaric anhydride 2a (1.00 g, 5.26 mmol), p-
anisidine (0.65 g, 5.26 mmol) and triethylamine (0.70 mL, 5.26 mmol), the title compound 3 was 
obtained as white crystals by recrystallization from EtOAc (1.23 g, 80%); mp = 248±250 oC; 
Anal. Calcd for C18H17NO3: C, 73.20; H, 5.80; N, 4.74. Found: C, 73.00; H, 5.52; N, 4.66; ȣmax 
/cm-1 (ATR) 1731 (m, C=O), 1672 (s, C=O), 1610 (s), 1511 (s); įH (400 MHz, CDCl3) 3.02 (dd, 
J = 17.2, 11.4 Hz, 2H), 3.18 (dd, J = 17.2, 4.4 Hz, 2H), 3.58 (tt, J = 11.4, 4.4 Hz, 1H), 3.85 (s, 
3H), 6.99±7.06 (m, 4H), 7.28±7.45 (m, 5H); įC (100 MHz, CDCl3) 34.7 (CH), 40.1 (2 × CH2), 
55.4 (CH3), 114.7 (2 × CH), 126.4 (2 × CH), 127.3 (C), 127.7 (CH), 129.2 (2 × CH), 129.3 (2 × 
CH), 140.5 (C) 159.5 (C), 172.0 (2 × C); MS (TOF MS ES+) m/z: 296 ([MH]+, 100%), 270 
(10%), 249 (40%), 241 (8%). 
1-(Phenylmethyl)-4-phenylpiperidin-2,6-dione 4a 
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Using general procedure E starting with 3-phenylglutaric anhydride 2a (1.50 g, 7.89 mmol), 
benzylamine (0.85 g, 7.89 mmol) and triethylamine (1.10 mL, 7.89 mmol), the title compound 
4a was obtained as white crystals by recrystallization from EtOAc / petroleum ether (40±60) 
(1.87 g, 85%); mp = 100±102 oC (lit.31 94±96 oC)ȣmax /cm-1 (ATR) 3031 (w, C-H), 1726 (m, 
C=O), 1668 (s, C=O); įH (400 MHz, CDCl3) 2.85 (dd, J = 17.2, 11.8 Hz, 2H), 3.05 (dd, J = 17.2, 
4.3 Hz, 2H), 3.38 (tt, J = 11.8, 4.3 Hz, 1H), 5.02 (s, 2H), 7.18±7.22 (m, 2H), 7.28±7.42 (m, 8H); 
įC (100 MHz, CDCl3) 34.6 (CH), 39.9 (2 × CH2), 42.9 (CH2), 126.3 (2 × CH), 127.5 (CH), 127.6 
(CH), 128.4 (2 × CH), 128.9 (2 × CH), 129.1 (2 × CH), 137.1 (C) 140.6 (C), 171.6 (2 × C); MS 
(TOF MS ES+) m/z: 280 ([MH]+, 100%). Only melting point and 1H NMR were cited in the 
literature.17,31 
1-(Phenylmethyl)-4-(2-fluorophenyl)piperidin-2,6-dione 4b 
Using general procedure E starting with glutaric anhydride 2b (2.00 g, 9.62 mmol), benzylamine 
(1.10 mL, 9.62 mmol) and triethylamine (1.34 mL, 9.62 mmol), the title compound 4b was 
obtained as white powder by recrystallization from EtOAc / petroleum ether (40±60) (1.7 g, 
60%); mp = 76±78 oC; Anal. Calcd for C18H16FNO2: C, 72.71; H, 5.42; N, 4.71. Found: C, 
72.38; H, 5.26; N, 4.57; ȣmax /cm-1 (ATR) 3068 (w, C-H), 1728 (m, C=O), 1672 (s, C=O); įH 
(400 MHz, CDCl3) 2.91 (dd, J = 16.9, 11.4 Hz, 2H), 3.04 (dd, J = 16.9, 4.0 Hz, 2H(?3.68 
(m, 1H), 5.02 (s, 2H), 7.07±7.13 (m, 3H), 7.27±7.34 (m, 4H), 7.42 (d, J = 7.0 Hz, 2H); įC (100 
MHz, CDCl3) 29.1 (CH), 38.3 (2 × CH2), 43.0 (CH2), 116.1 (d, JC-F = 22.1 Hz, CH), 124.7 (d, J 
C-F = 3.3 Hz, CH), 127.2 (d, J C-F = 4.0 Hz, CH), 127.4 (d, JC-F = 14.4 Hz, C), 127.6 (CH), 128.5 
(2 × CH), 129.0 (2 × CH), 129.3 (d, J C-F = 8.5 Hz, CH), 137.1 (C), 160.8 (d, J C-F = 246.6 Hz, 
C), 171.4 (2 × C); įF (235 MHz, CDCl3) -117.4; MS (TOF MS ES+) m/z: 298 ([MH]+, 100%).  
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1-(Phenylmethyl)-4-(4-fluorophenyl)piperidin-2,6-dione 4c17 
Using general procedure E starting with glutaric anhydride 2c (4.00 g, 19.20 mmol), 
benzylamine (2.10 mL, 19.2 mmol) and triethylamine (2.60 mL, 19.20 mmol), the title 
compound 4c was obtained as white powder by recrystallization from EtOAc / petroleum ether 
(40±60) (1.20 g, 67%); mp = 120±122 oC; Anal. Calcd for C18H16FNO2: C, 72.71; H, 5.42; N, 
4.71. Found: C, 72.47; H, 5.31; N, 4.67; ȣmax /cm-1 (ATR) 2955 (w, C-H), 1718 (m, C=O), 1672 
(s, C=O), 1604 (m), 1512 (s); įH (400 MHz, CDCl3) 2.81 (dd, J = 17.1, 11.5 Hz, 2H), 3.00 (dd, J 
= 17.1, 4.3 Hz, 2H), 3.37 (tt, J = 11.5, 4.3 Hz, 1H), 5.01 (s, +(씀7m, 2H(?7.17 
(m, 2H), 7.28±7.32 (m, 3H), 7.38(?7.41 (m, 2H); įC (100 MHz, CDCl3) 33.9 (CH), 40.0 (2 × 
CH2), 42.9 (CH2), 115.9 (d, J C-F = 21.5 Hz, 2 × CH), 127.6 (CH), 127.9 (d, J C-F = 7.0 Hz, 2 × 
CH), 128.4 (2 × CH), 128.9 (2× CH), 136.3 (d, J C-F = 3.0 Hz, C), 137.0 (C), 162.0 (d, J C-F = 
246.6 Hz, C), 171.3 (2 × C); įF (235 MHz, CDCl3) -114.7; HRMS (ESI+TOF): calcd for 
C18H17FNO2 ([MH]+), 298.1243; found, 298.1233. Only 1H NMR data was reported in the 
literature.17 
1-(Phenylmethyl)-4-(2-methylphenyl)piperidin-2,6-dione 4d 
Using general procedure E starting with glutaric anhydride 2d (1.50 g, 7.35 mmol), benzylamine 
(0.81 mL, 7.35 mmol) and triethylamine (1.02 mL, 7.35 mmol), the title compound 4d was 
obtained as white powder by recrystallization from EtOAc / petroleum ether (40±60) (1.88 g, 
87%); mp = 138±140 o&ȣmax /cm-1 (ATR) 3017 (w, C-H), 1728 (m, C=O), 1670 (s, C=O), 1605 
(w); įH (400 MHz, CDCl3) 2.37 (s, 3H), 2.81 (dd, J = 17.2, 11.8 Hz, 2H), 2.98 (dd, J = 17.2, 4.3 
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Hz, 2H), 3.58 (tt, J = 11.8, 4.3 Hz, 1H), 5.04 (s, 2H), 7.09±7.12 (m, 1H), 7.20(?7.23 (m, 3H), 
7.27±7.37 (m, 3H), 7.43(?7.46 (m, 2H); įC (100 MHz, CDCl3) 19.3 (CH3), 30.7 (CH), 39.3 (2 × 
CH2), 43.0 (CH2), 124.5 (CH), 126.8 (CH), 127.4 (CH), 127.6 (CH), 128.5 (2 × CH), 129.1 (2 × 
CH), 131.1 (CH), 135.6 (C), 137.1 (C), 138.7 (C), 171.9 (2 × C); HRMS (ESI+TOF): calcd for 
C19H20NO2 ([MH]+), 294.1494; found, 294.1485.  
1-(Phenylmethyl)-4-(4-methylphenyl)piperidin-2,6-dione 4e 
Using general procedure E starting with glutaric anhydride 2e (5.00 g, 24.5 mmol), benzylamine 
(2.67 mL, 24.5 mmol) and triethylamine (3.40 mL, 24.5 mmol), the title compound 4e was 
obtained as white powder by recrystallization from EtOAc / petroleum ether (40±60) (5.10 g, 
71%); mp = 106±108 o&ȣmax /cm-1 (ATR) 2955 (w, C-H), 1727 (m, C=O), 1669 (s, C=O); įH 
(400 MHz, CDCl3) 2.36 (s, 3H), 2.82 (dd, J = 17.1, 11.8 Hz, 2H), 3.03 (dd, J = 17.1, 4.2 Hz, 
2H), 3.34 (tt, J = 11.8, 4.2 Hz, 1H), 5.02 (s, 2H), 7.09 (d, J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 
2H), 7.26±7.35 (m, 3H), 7.39(?7.52 (m, 2H); įC (100 MHz, CDCl3) 21.0 (CH3), 34.2 (CH), 40.1 
(2 × CH2), 42.9 (CH2), 126.2 (2 × CH), 127.5 (CH), 128.4 (2 × CH), 128.9 (2 × CH), 129.7 (2 × 
CH), 137.1 (C), 137.3 (C), 138.6 (C), 171.7 (2 × C); HRMS (ESI+TOF): calcd for C19H20NO2 
([MH]+), 294.1494; found, 294.1504.  
1-(Phenylmethyl)-4-(1-naphthyl)piperidin-2,6-dione 4f 
Using general procedure E starting with glutaric anhydride 2f (2.00 g, 8.33 mmol), benzylamine 
(0.90 mL, 8.33 mmol) and triethylamine (1.16 mL, 8.33 mmol), the title compound 4f was 
obtained as white powder by recrystallization from EtOAc / petroluem ether (40±60) (1.42 g, 
52%); mp = 116±118 o&ȣmax /cm-1 (ATR) 3052 (w, C-H), 2964 (w, C-H), 1723 (m, C=O), 1672 
(s, C=O), 1598 (m); įH (400 MHz, CDCl3) 2.98 (dd, J = 16.9, 10.8 Hz, 2H), 3.21 (dd, J = 16.9, 
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3.8 Hz, 2H), 4.15±4.22 (m, 1H), 5.08 (s, 2H), 7.23±7.38 (m, 4H), 7.40±7.48 (m, 3H), 7.53±7.61 
(m, 2H), 7.82 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H); įC (100 
MHz, CDCl3) 30.0 (CH), 39.5 (2 × CH2), 43.1 (CH2), 122.2 (CH), 122.3 (CH), 125.5 (CH), 
126.1 (CH), 126.8 (CH), 127.6 (CH), 128.3 (CH), 128.5 (2 × CH), 129.1 (2 × CH), 129.3 (CH), 
130.8 (C), 134.1 (C), 136.3 (C), 137.1 (C), 171.8 (2 × C); HRMS (ESI+TOF): calcd for 
C22H20NO2 ([MH]+), 330.1494; found, 330.1504. 
1-(Phenylmethyl)-4-methylpiperidin-2,6-dione 4g17 
Using general procedure E starting with glutaric anhydride 2g (3.50 g, 27.3 mmol), benzylamine 
(2.93 g, 27.3 mmol) and triethylamine (3.82 mL, 27.3 mmol), the title compound 4g was 
obtained as white powder by recrystallization from 50% EtOAc / hexane (4.13 g, 70%); mp = 
68±70 oC; Anal. Calcd for C13H15NO2: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.74; H, 6.87; N, 
6.46ȣmax /cm-1 (ATR) 2961 (w, C-H), 1721 (m, C=O), 1665 (s, C=O); įH (400 MHz, CDCl3) 
1.08 (d, J = 6.4 Hz, 3H), 2.17±2.29 (m, 1H), 2.31±2.37 (m, 2H), 2.80 (dd, J = 16.7, 3.8 Hz, 2H), 
4.97 (s, 2H), 7.24±7.32 (m, 3H), 7.37±7.39 (m, 2H); įC (100 MHz, CDCl3) 20.3 (CH3), 24.5 
(CH), 40.7 (2 × CH2), 42.7 (CH2), 127.4 (CH), 128.4 (2 × CH), 128.8 (2 × CH), 137.3 (C), 172.1 
(2 × C); MS (TOF MS ES+) m/z: 218 ([MH]+, 100%). Only 1H NMR was cited in literature.17 
1-(Phenylmethyl)-4-isopropylpiperidin-2,6-dione 4h 
Using general procedure E starting with glutaric anhydride 2h (2.00 g, 12.8 mmol), benzylamine 
(1.37 g, 12.8 mmol) and triethylamine (1.80 mL, 12.8 mmol), a yellowish liquid was obtained 
that turned to a yellowish solid upon standing. The solid was purified via flash column 
chromatography eluting with EtOAc / petroleum ether (40±60) (3:7) to afford the title compound 
4h as colourless liquid which turned to a white solid upon standing (2.10 g, 67%); mp = 45±46 
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oC; Anal. Calcd for C15H19NO2: C, 73.44; H, 7.81; N, 5.71. Found: C, 73.24; H, 7.75; N, 5.53; 
ȣmax /cm-1 (ATR) 2960 (w), 2874 (w), 1724 (m, C=O), 1668 (s, C=O); įH (400 MHz, CDCl3) 
0.95 (d, J = 6.7 Hz, 6H), 1.57 (octet, J = 6.7 Hz, 1H), 1.81(?1.91 (m, 1H), 2.35 (dd, J = 17.1, 12.3 
Hz, 2H), 2.82 (dd, J = 17.1, 4.0 Hz, 2H), 4.96 (s, 2H), 7.23±7.32 (m, 3H), 7.39 [(AX)2, 2H]; įC 
(100 MHz, CDCl3) 19.2 (2 × CH3), 31.4 (CH), 35.5 (CH), 36.9 (2 × CH2), 42.8 (CH2), 127.4 
(CH), 128.4 (2 × CH), 128.8 (2 × CH), 137.2 (C), 172.6 (2 × C); HRMS (ESI+TOF): calcd for 
C15H20NO2 ([MH]+), 246.1494; found, 246.1504.  
1-(Phenylmethyl)-4-tert-butylpiperidin-2,6-dione 4i 
Using general procedure E starting with glutaric anhydride 2i (1.30 g, 7.65 mmol), benzylamine 
(0.89 g, 7.65 mmol) and triethylamine (1.10 mL, 7.65 mmol), a yellowish solid was obtained. 
The solid was purified via flash column chromatography eluting with EtOAc : petroleum ether 
(40±60) (3:7) to afford the title compound 4i as colourless liquid which turned to a white solid 
upon standing (1.12 g, 57%); mp = 44±46 oC; ȣmax /cm-1 (ATR) 2951 (w, C-H), 2874 (w, C-H), 
1719 (m, C=O), 1666 (s, C=O); įH (400 MHz, CDCl3) 0.93 (s, 9H), 1.86 (tt, J = 13.5, 3.8 Hz, 
1H(?2.37 (m, 2H), 2.83 (dd, J = 17.0, 3.8 Hz, 2H), 4.96 (s, 2H), 7.24±7.33 (m, 3H), 7.37±
7.40 (m, 2H); įC (100 MHz, CDCl3) 26.5 (3 × CH3), 31.8 (C), 35.0 (2 × CH2), 39.2 (CH), 42.8 
(CH2), 127.5 (CH), 128.4 (2 × CH), 128.8 (2 × CH), 137.2 (C), 172.9 (2 × C); HRMS 
(ESI+TOF): calcd for C16H22NO2 ([MH]+), 260.1651; found, 260.1650. 
1-(2-Methylphenylmethyl)-4-phenylpiperidin-2,6-dione 5 
Using general procedure E starting with 3-phenylglutaric anhydride 2a (1.70 g, 8.95 mmol), 2-
methylbenzylamine (1.09 g, 8.95 mmol) and triethylamine (1.25 mL, 8.95 mmol), the title 
compound 5 was obtained as white crystals by recrystallization from EtOAc / petroleum ether 
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(40±60) (1.87 g, 71%); mp = 123±125 oC; Anal. Calcd for C19H19NO2: C, 77.79; H, 6.53; N, 
4.77. Found: C, 77.53; H, 6.51; N, 4.76ȣmax /cm-1 (ATR) 2973 (w, C-H), 1727 (m, C=O), 1667 
(s, C=O); įH (250 MHz, CDCl3) 2.44 (s, 3H), 2.91 (dd, J = 17.0, 11.5 Hz, 2H), 3.10 (dd, J = 17.0, 
4.4 Hz, 2H), 3.46 (tt, J = 11.5, 4.4 Hz, 1H), 5.01 (s, 2H), 6.96 [(AX)2, 1H], 7.08±7.18 (m, 3H), 
7.23±7.27 (m, 2H), 7.32±7.44 (m, 3H); įC (100 MHz, CDCl3) 19.4 (CH3), 34.6 (CH), 39.9 (2 × 
CH2), 40.4 (CH2), 126.0 (CH), 126.0 (CH), 126.4 (2 × CH), 127.1 (CH), 127.7 (CH), 129.1 (2 × 
CH), 130.3 (CH), 134.7 (C), 135.8 (C), 140.5 (C), 171.7 (2 × C); MS (TOF MS ES+) m/z: 294 
([MH]+, 100%).  
1-(2-Methoxyphenylmethyl)-4-phenylpiperidin-2,6-dione 6 
Using general procedure E starting with 3-phenylglutaric anhydride 2a (2.00 g, 10.5 mmol), 2-
methoxybenzylamine (1.37 mL, 10.5 mmol) and triethylamine (1.47 mL, 10.5 mmol), the title 
compound 6 was obtained as white crystals by recrystallization from EtOAc / petroleum ether 
(40±60) (1.97 g, 60%); mp = 98±100 oC; Anal. Calcd for C19H19NO3: C, 73.77; H, 6.19; N, 4.53. 
Found: C, 73.50; H, 6.06; N, 4.44ȣmax /cm-1 (ATR) 2960 (w, C-H), 1728 (m, C=O), 1671 (s, 
C=O), 1603 (m); įH (400 MHz, CDCl3) 2.91 (dd, J = 17.1, 11.5 Hz, 2H), 3.08 (dd, J = 17.1, 4.3 
Hz, 2H), 3.44 (tt, J = 11.5, 4.3 Hz, 1H), 3.86 (s, 3H), 5.08 (s, 2H), 6.88±6.96 (m, 3H), 7.22±7.28 
(m, 3H), 7.31±7.35 (m, 1H), 7.38±7.40 (m, 2H); įC (100 MHz, CDCl3) 34.6 (CH), 38.5 (2 × 
CH2), 39.9 (CH2), 55.4 (CH3), 110.4 (CH), 120.3 (2 × CH), 124.8 (C), 126.5 (2 × CH), 127.0 
(CH), 127.6 (CH), 128.2 (CH), 129.1 (CH), 140.7 (C) 157.1 (C), 171.5 (2 × C); HRMS 
(ESI+TOF): calcd for C19H20NO3 ([MH]+), 310.1443; found, 310.1451.  
General Procedure F for the asymmetric reduction of 4-phenylglutarimides using B-OMe 
catalyst 7 followed by conversion to the corresponding lactam 
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A solution of (1R, 2S)-cis-1-amino-indan-2-ol (0.15 g, 1.00 mmol) in THF (3 mL) was treated 
with trimethylborate (0.10 mL, 1.00 mmol) and allowed to stir for 45 min. The solution was then 
diluted to 5 mL by further addition of THF, to give the catalyst 7 as a stock solution. The 
glutarimide (1.00 mmol) was dissolved in dry DCM (30 mL) under a nitrogen atmosphere and 
this solution was treated with the catalyst stock solution (0.50 mL, 10 mol%) then a drop-wise 
addition of BH3.THF (1.00 mL, 1.00 mmol), and allowed to stir at rt for 3 h (for N-PMP 
glutarimide) or 24 h (for N-Bn glutarimide). The reaction was quenched by the addition of 
MeOH (5 mL) and 1M HCl (5 mL), and extracted with CH2Cl2 (3 × 15 mL). The combined 
organic extracts were dried over MgSO4 and filtered. The solvent was removed in vacuo to give 
the crude hydroxy-lactam as a white powder which was immediately re-dissolved in CH2Cl2 (25 
mL) and treated with TFA (1 mL) and triethylsilane (1 mL) in CH2Cl2 (5 mL). This mixture was 
allowed to stir at rt for 1 h, after which the solution was added to an ice-water mixture (15 mL) 
followed by extraction with CH2Cl2 (3 × 15 mL). The combined organic extracts were washed 
with saturated NaHCO3 (15 mL), dried over MgSO4 and filtered. The solvent was removed in 
vacuo to give a white solid, which was purified via flash column chromatography. 
General Procedure G for the asymmetric reduction of glutarimides using B-Me catalyst 8 
followed by conversion to the corresponding lactam 
A suspension of (1R, 2S)-cis-amino-2-indanol (0.15 g, 1.00 mmol) in dry toluene (3 mL) was 
treated with trimethylboroxine (0.05 mL, 0.33 mmol) and allowed to stir under nitrogen for 30 
min. Dry toluene (5 mL) was added and the reaction distilled until approximately 2 mL of 
solvent remained. This procedure was repeated twice after which the final volume of toluene was 
removed under pressure to give a yellow solid. Dry dichloromethane (5 mL) was added to give a 
stock solution of the B-Me catalyst 8. The catalyst (0.5 mL, 10 mol %) was added to the solution 
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of the glutarimide substrate (1.00 mmol) in dry dichloromethane (30 mL) followed by a drop-
wise addition of BH3.THF (1 mL, 1.00 mmol). The solution was then allowed to stir at room 
temperature for 3 h (for N-PMP glutarimide) or 24 h (for N-Bn glutarimides). The reaction was 
finally quenched by addition of MeOH (2 mL) and 1M HCl (2 mL), extracted with CH2Cl2 (3 × 
15 mL), dried over MgSO4 and filtered. The solvent was evaporated in vacuo to give the crude 
hydroxy-lactam as a white powder which was immediately re-dissolved in CH2Cl2 (30 mL) and 
treated with TFA (1 mL) and triethylsilane (1 mL) in CH2Cl2 (5 mL). This mixture was allowed 
to stir at rt for 1 h, after which the solution was added to an ice-water mixture (15 mL) followed 
by extraction with CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with 
saturated NaHCO3 (3 × 15 mL), dried over MgSO4 and filtered. The solvent was removed in 
vacuo to give a crude white solid, which was purified via flash column chromatography eluting 
with EtOAc / petroleum ether (40±60) (7:3). 
Procedure for the asymmetric reduction of N-(benzyl)-4-phenylpiperidin-2,6-dione 4a 
using catalyst 9 followed by conversion to the corresponding lactam 10b 
A suspension of (S)-(±)-ĮĮ-diphenyl-2-pyrrolidinemethanol (0.25 g, 1.00 mmol) in dry toluene 
(3 mL) was treated with trimethylboroxine (0.05 mL, 0.33 mmol) and allowed to stir under 
nitrogen for 30 min. Dry toluene (5 mL) was added and the reaction distilled until approximately 
2 mL of solvent remained. This procedure was repeated twice after which the final volume of 
toluene was removed under pressure to give a yellow solid. Dry dichloromethane (5 mL) was 
added to give a stock solution of the B-Me CBS catalyst. The catalyst (0.50 mL, 10 mol %) was 
added to the solution of the glutarimide substrate 4a (0.28 g, 1.00 mmol) in dry dichloromethane 
(30 mL) followed by a drop-wise addition of BH3.THF (1 mL, 1.00 mmol). The solution was 
then allowed to stir at room temperature for 24 h. The reaction was finally quenched by addition 
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of MeOH (2 mL) and 1M HCl (2 mL), extracted with CH2Cl2 (3 × 15 mL), dried over MgSO4 
and filtered. The solvent was evaporated in vacuo to give the crude hydroxy-lactam as a white 
powder which was immediately re-dissolved in CH2Cl2 (30 mL) and treated with TFA (1 mL) 
and triethylsilane (1 mL) in CH2Cl2 (5 mL). This mixture was allowed to stir at rt for 1 h, after 
which the solution was added to an ice-water mixture (15 mL) followed by extraction with 
CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with saturated NaHCO3 (15 
mL), dried over MgSO4 and filtered. The solvent was removed in vacuo to give a crude white 
solid, which was purified via flash column chromatography eluting with EtOAc : petroleum ether 
(40±60) (7:3) to afford the corresponding lactam as white solid (0.03 g, 13% over 2 steps, 14% 
ee determined by HPLC on a Lux 3u Cellulose-2 column (hexane/2-propanol = 80/20, flow rate 
= 1.0 mL/min, tminor = 21.1 min, tmajor = 23.1 min); All analytical data corresponds to those 
reported for compound 10b. 
(4R)-1-(4-Methoxyphenyl)-4-phenylpiperidin-2-one 10a 
Using glutarimide 3 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid using 
general procedure G (0.07 g, 33% over 2 steps, 95% ee determined by HPLC on a 
CELLULOSE-1 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tminor = 27.3 min, 
tmajor = 29.9 min); mp = 204±206 oC; ሾȽሿୈଶ଴ + 6.0 (c 1.3, CHCl3; 95% ee); vmax / cm-1 (ATR) 2940 
(w, C-H), 1640 (s, C=O), 1620 (m, C=O), 1605 (m, C=O), 1506 (s, C=C); įH (400 MHz, CDCl3) 
2.11±2.21 (m, 1H), 2.23±2.30 (m, 1H), 2.73 (dd, J = 17.5, 10.8 Hz, 1H), 2.92 (ddd, J = 17.5, 5.3 
Hz, 1.9 Hz, 1H), 3.29 (tdd, J = 10.8, 5.3 Hz, 3.4 Hz, 1H), 3.65 (ddd, J = 10.8, 5.3, 3.4 Hz, 1H), 
(?3.81 (m, 1H), 3.84 (s, 3H), 6.96 [(AX)2, 2H], 7.22 [(AX)2, 2H], 7.28±7.32 (m, 3H), 7.38±
7.42 (m, 2H); įC (100 MHz, CDCl3) 30.7 (CH2), 38.8 (CH), 39.8 (CH2), 51.0 (CH2), 55.5 (CH3), 
114.6 (2 × CH), 126.6 (2 × CH), 126.9 (CH), 127.4 (2 × CH), 128.8 (2 × CH), 135.9 (C), 143.4 
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(C), 158.3 (C), 169.6 (C); HRMS (ESI+TOF): calcd for C18H20NO2 ([MH]+), 282.1494; found, 
282.1493.  
 (4R)-1-(Phenylmethyl)-4-phenylpiperidin-2-one 10b20 
Using glutarimide 4a (0.30 g, 1.00 mmol) the title compound 10b was obtained as a white solid 
using general procedure G (0.16 g, 60% over 2 steps, 90% ee determined by HPLC on a Lux 3P 
CELLULOSE-2 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tmajor = 23.5 min, 
tminor = 26.1 min); mp = 80±82 oC (lit.32 (?90 oC); ሾȽሿୈଶ଴ + 33.0 (c 1.1, CHCl3; 90% ee), lit.20 ሾȽሿୈଶ଴ + 35.0 (c 1.1, CHCl3, 92.5% ee); vmax /cm-1 (ATR) 1619 (s, C=O), 1494 (m, C=C); įH (400 
MHz, CDCl3) 1.97 (dtd, J = 13.2, 10.8, 6.0 Hz, 1H), 2.07±2.14 (m, 1H), 2.63 (dd, J = 17.5, 11.0 
Hz, 1H), 2.83 (ddd, J = 17.5, 5.2, 2.0 Hz, 1H), 3.13 (tdd, J = 11.0, 5.2, 3.1 Hz, 1H), 3.26±3.37 
(m, 2H), 4.59 (d, J = 14.5 Hz, 1H), 4.77 (d, J = 14.5 Hz, 1H), 7.21±7.39 (m, 10H); įC (100 MHz, 
CDCl3) 30.3 (CH2), 38.7 (CH), 39.5 (CH2), 46.4 (CH2), 50.0 (CH2), 126.5 (2 × CH), 126.8 (CH), 
127.5 (CH), 128.2 (2 × CH), 128.6 (2 × CH), 128.8 (2 × CH), 137.1 (C), 143.4 (C), 169.3 (C); 
MS (EI+) m/z: 265 ([M]+, 100%), 174 (12), 131 (32), 104 (230), 131 (32), 91 (70). All data are in 
accordance with literature.20, 32, 33 
(4R)-1-(2-Methylbenzyl)-4-phenylpiperidin-2-one 10c 
Using glutarimide 5 (0.30 g, 1.00 mmol) the title compound 10c was obtained as a white solid 
using general procedure G (0.07 g, 25% over 2 steps, 88% ee determined by HPLC on a Lux 3P 
CELLULOSE-2 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tmajor = 20.6 min, 
tminor = 22.3 min); mp = 72±74 oC; ሾȽሿୈଶ଴ + 26.6 (c 0.8, CHCl3; 88% ee); Anal. Calcd for 
C19H21NO: C, 81.68; H, 7.58; N, 5.01. Found: C, 81.81; H, 7.82; N, 4.85; vmax/ cm-1 (ATR) 3024 
(w, C-H), 2915 (w, C-H), 1627 (s, C=O), 1605 (m, C=C); įH (400 MHz, CDCl3) 1.93±2.03 (m, 
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1H), 2.09±2.15 (m, 1H), 2.34 (s, 3H), 2.64 (dd, J = 17.5, 11.1 Hz, 1H), 2.88 (ddd, J = 17.5, 5.2, 
2.1 Hz, 1H), 3.15 (tdd, J = 11.1, 5.2, 3.1 Hz, 1H), 3.22±3.31 (m, 2H), 4.63 (d, J = 15.1 Hz, 1H), 
4.81 (d, J = 15.1 Hz, 1H), 7.17±7.29 (m, 7H), 7.35±7.39 (m, 2H); įC (100 MHz, CDCl3) 19.25 
(CH3), 30.3 (CH2), 38.7 (CH), 39.5 (CH2), 46.3 (CH2), 47.7 (CH2), 126.1 (CH), 126.5 (2 × CH), 
126.8 (CH), 127.5 (CH), 128.1 (CH), 128.8 (2 × CH), 130.5 (CH), 134.5 (C), 136.6 (C), 143.4 
(C), 169.2 (C); HRMS (ESI+TOF): calcd for C19H22NO ([MH]+), 280.1701; found, 280.1713. 
(4R)-1-(2-Methoxybenzyl)-4-phenylpiperidin-2-one 10d 
Using glutarimide 6 (0.30 g, 1.00 mmol) the title compound 10d was obtained as a white solid 
using general procedure G (0.06 g, 21% over 2 steps, 90% ee determined by HPLC on a Lux 3P 
CELLULOSE-2 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tmajor = 21.3 min, 
tminor = 23.6 min); mp = 80±82 oC; ሾȽሿୈଶ଴ + 21.7 (c 1.0, CHCl3; 90% ee); vmax / cm-1 (ATR) 2940 
(w, C-H), 1636 (s, C=O); įH (400 MHz, CDCl3) 1.95±2.03 (m, 1H), 2.09±2.13 (m, 1H), 2.62 (dd, 
J = 17.5, 11.1 Hz, 1H), 2.84 (ddd, J = 17.5 Hz, 5.3, 2.0 Hz, 1H), 3.15 (tdd, J = 11.1, 5.3, 3.2 Hz, 
1H), 3.31±3.37 (m, 2H), 3.86 (s, 3H), 4.65 (d, J = 15.1 Hz, 1H), 4.77 (d, J = 15.1 Hz, 1H), 6.90 
(d, J = 8.0 Hz, 1H), 6.97 (td, J = 7.5, 0.9 Hz, 1H), 7.23±7.30 (m, 5H), 7.34±7.38 (m, 2H); įC (100 
MHz, CDCl3) 30.4 (CH2), 38.7 (CH), 39.5 (CH2), 44.5 (CH2), 46.8 (CH2), 55.4 (CH3), 110.3 
(CH), 120.7 (CH), 125.1 (C), 126.6 (2 × CH), 126.8 (CH), 128.5 (CH), 128.7 (2 × CH), 129.1 
(CH), 143.6 (C), 157.6 (C), 169.4 (C); HRMS (EI+): calcd for C19H21NO2 (M+), 295.1572; found, 
295.1563; MS (EI+) m/z: 295 (M+, 100%), 264 (50), 176 (27), 149 (35), 121 (60), 91 (85).  
1-(4-Methoxyphenyl)-4-phenylpiperidine 11a 
Using general procedure G and glutarimide 3 (0.30 g, 1.00 mmol) the title compound 11a was 
obtained as white crystals (0.08 g, 30% over 2 steps); mp = 150±152 oC; Anal. Calcd for 
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C18H21NO: C, 80.86; H, 7.92; N, 5.24. Found: C, 80.74; H, 7.91; N, 5.12; vmax / cm-1 (ATR) 2953 
(w, C-H), 2938 (m, C-H), 2917 (m, C-H), 2810 (m, C-H), 1508 (s, C=O); įH (400 MHz, CDCl3) 
1.95±1.96 (m, 4H), 2.61±2.69 (m, 1H), 2.75±2.82 (m, 2H), 3.65±3.69 (m, 2H), 3.81 (s, 3H), 6.90 
[(AX)2, 2H], 7.00 [(AX)2, 2H], 7.24±7.38 (m, 5H); įC (100 MHz, CDCl3) 33.6 (2 × CH2), 42.4 
(CH), 52.2 (2 × CH2), 55.6 (CH3), 114.4 (2 × CH), 118.9 (2 × CH), 126.3 (CH), 126.9 (2 × CH), 
128.5 (2 × CH), 146.2 (C), 146.4 (C), 153.8 (C); HRMS (ESI+TOF): calcd for C18H22NO 
([MH+]), 268.1701; found, 268.1693. Only 1H NMR and low resolution mass spectrometry data 
were provided in the literature. The literature 1H NMR data is mis-assigned.34 
1-(Phenylmethyl)-4-phenylpiperidine 11b 
Using general procedure G and glutarimide 3 (0.30 g, 1.00 mmol) the title compound 11b was 
obtained as an undesired product as yellow oil (0.03 g, 12% over 2 steps); vmax / cm-1 (ATR) 
3026 (w, C-H), 2933 (m, C-H), 2798 (m, C-H), 2754 (m, C-H), 1493 (m, C=O); įH (250 MHz, 
CDCl3) 1.75±1.95 (m, 4H), 2.05±2.21 (m, 2H), 2.48±2.60 (m, 1H), 3.03±3.10 (m, 2H), 3.60 (s, 
2H), 7.20±7.40 (m, 10H); įC (75 MHz, CDCl3) 33.6 (2 × CH2), 42.8 (CH), 54.3 (2 × CH2), 63.5 
(CH2), 126.1 (CH), 126.9 (2 × CH), 127.0 (CH), 128.2 (2 × CH), 128.4 (2 × CH), 129.2 (2 × 
CH), 138.6 (C), 146.6 (C); HRMS (ESI+TOF): calcd for C18H22N ([MH+]), 252.1752; found, 
252.1764. All data are in accordance with literature.35 
(6R) and (6S)-(4R)-5-Hydroxy-1-(4-methoxyphenyl)-4-phenylpiperidin-2-one 12 
Using general procedure G with glutarimide 3 (0.30 g, 1.00 mmol) but halting the reaction and 
purifying the crude hydroxy-lactam before conversion to the N-PMP lactam gave the title 
compound 12 as a white powder in a 2:1 diastereomeric ratio (0.06 g, 20%); mp = 156±158 oC; ሾȽሿୈଶ଴  + 18.2 (c 1.7, CHCl3); vmax /cm-1 (ATR) 3188 (w, O-H), 2935 (w, C-H), 1644 (m, C=O), 
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1620 (s, C=O), 1602 (s, C=O), 1507 (s, C=C); įH (400 MHz, CDCl3) major diastereoisomer 
2.60±2.74 (m, 2H), 2.86±2.96 (m, 2H), 3.21±3.31 (m, 2H), 3.84 (s, 3H), 5.30±5.34 (m, 1H), 
6.96±6.98 (m, 3H), 7.28±7.30 (m, 6H); įC (100 MHz, CDCl3) major diastereoisomer 30.7 (CH2), 
33.1 (CH), 51.0 (CH2), 55.5 (CH3), 81.9 (CH), 114.8 (2 × CH), 126.7 (2 × CH), 127.4 (CH), 
128.8 (2 × CH), 129.2 (2 × CH), 133.4 (C), 143.1 (C), 158.9 (C), 170.0 (C); HRMS (ESI+TOF): 
calcd for C18H19NO3 ([MH]+), 298.1443; found, 298.1446. 
(4R)-1-(Phenylmethyl)-4-(2-fluorophenyl)piperidin-2-one 13b 
Using glutarimide 4b (0.30 g, 1.00 mmol) the title compound 13b was obtained as a white solid 
using general procedure G (0.17 g, 61% over 2 steps, 86% ee determined by HPLC on a Lux 3P 
CELLULOSE-2 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tmajor = 16.4 min, 
tminor = 18.2 min); mp = 60±62 oC; ሾȽሿୈଶ଴ +20.1 (c 2.1, CHCl3; 86% ee); vmax / cm-1 (ATR) 2925 
(w, C-H), 1616 (s, C=O), 1580 (m, C=C); įH (400 MHz, CDCl3) 1.98±2.10 (m, 2H), 2.64 (dd, J = 
17.4, 10.8 Hz, 1H), 2.85 (ddd, J = 17.4, 5.3 Hz, 1.9 Hz, 1H), 3.25±3.38 (m, 2H), 3.45 (td, J = 
10.8, 5.3, 3.9 Hz, 1H), 4.58 (d, J = 14.6 Hz, 1H), 4.76 (d, J = 14.6 Hz, 1H), 7.03±7.36 (m, 9H); 
įC (100 MHz, CDCl3) 28.9 (CH2), 32.2 (d, JC-F = 1.5 Hz, CH), 38.0 (CH2), 46.3 (CH2), 50.1 
(CH2), 115.6 (d, JC-F = 22.4 Hz, CH), 124.4 (d, JC-F = 3.5 Hz, CH), 127.3 (d, JC-F = 4.6 Hz, CH), 
127.5 (CH), 128.2 (2 × CH), 128.3 (d, JC-F = 8.4 Hz, CH), 128.7 (2 × CH), 130.1 (d, JC-F = 14.2 
Hz, C), 137.0 (C), 160.6 (d, J C-F = 245.8 Hz, C), 169.1 (C); įF (235 MHz, CDCl3) -118.6; HRMS 
(EI+): calcd for C18H18FNO (M+), 283.1372; found, 283.1382; MS (EI+) m/z: 283 (M+, 100%), 
149 (50), 109 (25), 103 (58) 105 (93), 91 (95), 77 (98).  
(4R)-1-(Phenylmethyl)-4-(4-fluorophenyl)piperidin-2-one 13c 
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Using glutarimide 4c (0.30 g, 1.00 mmol) the title compound 13c was obtained as a white solid 
using general procedure G (0.15 g, 54% over 2 steps, 88% ee determined by HPLC on a 
CHIRALPAK IA column (hexane/2-propanol = 93/7, flow rate = 1.0 mL/min, tminor = 38.2 min, 
tmajor = 40.0 min); mp = 114±116 oC; ሾȽሿୈଶ଴ +30.0 (c 1.1, CHCl3; 88% ee, lit.20 ሾȽሿୈଶ଴ + 33.0 (c 
1.07, CHCl3); vmax / cm-1 (ATR) 3071 (w, C-H), 1625 (s, C=O), 1601 (m, C=C); įH (400 MHz, 
CDCl3) 1.87±1.97 (m, 1H), 2.07±2.10 (m, 1H), 2.57 (dd, J = 17.4, 11.0 Hz, 1H), 2.83 (dd, J = 
17.4, 3.4 Hz, 1H), 3.09(?3.14 (m, 1H), 3.25±3.36 (m, 2H), 4.57 (d, J = 14.5 Hz, 1H), 4.77 (d, J = 
14.5 Hz, 1H), 7.03 [(AX)2, 2H], 7.18 [(AX)2, 2H], 7.28±7.38 (m, 5H); įC (100 MHz, CDCl3) 
30.3 (CH2), 38.0 (CH), 39.6 (CH2), 46.2 (CH2), 50.0 (CH2), 115.5 (d, JC-F = 21.2 Hz, 2 × CH), 
127.5 (CH), 128.0 (d, JC-F = 7.8 Hz, 2 × CH), 128.2 (2 × CH), 128.7 (2× CH), 137.1 (C), 139.1 
(d, JC-F = 3.0 Hz, C), 161.7 (d, JC-F = 245.0 Hz, C), 169.1 (C); įF (235 MHz, CDCl3) -116.0; 
HRMS (ESI+TOF): calcd for C18H19FNO ([MH+]), 284.1451; found, 284.1437. All data are in 
accordance with literature. 20, 33, 36 
(4R)-1-(Phenylmethyl)-4-(2-methylphenyl)piperidin-2-one 13d 
Using glutarimide 4d (0.30 g, 1.00 mmol) the title compound 13d was obtained as a white solid 
using general procedure G (0.14 g, 51% over 2 steps, 82% ee determined by HPLC on a Lux 3P 
CELLULOSE-2 column (hexane/2-propanol = 80/20, flow rate = 1.0 mL/min, tminor = 15.3 min, 
tmajor = 18.3 min); mp = 68±70 oC; ሾȽሿୈଶ଴ +39.4 (c 0.3, CHCl3; 82% ee); vmax / cm-1 (ATR) 2925 
(w, C-H), 1626 (s, C=O), 1587 (m, C=C); įH (400 MHz, CDCl3) 2.01±2.04 (m, 2H), 2.37 (s, 3H), 
2.56 (dd, J = 17.5, 11.0 Hz, 1H), 2.81 (ddd, J = 17.5, 5.2, 1.9 Hz, 1H), 3.28±3.37 (m, 3H), 4.55 
(d, J = 14.5 Hz, 1H), 4.85 (d, J = 14.5 Hz, 1H), 7.16±7.22 (m, 4H), 7.33±7.40 (m, 5H); įC (100 
MHz, CDCl3) 19.3 (CH3), 29.3 (CH2), 34.6 (CH), 39.0 (CH2), 46.5 (CH2), 50.1 (CH2), 125.0 
(CH), 126.5 (CH), 126.6 (CH), 127.5 (CH), 128.3 (2 × CH), 128.7 (2 × CH), 130.7 (CH), 135.3 
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(C), 137.2 (C), 141.5 (C) 169.6 (C); HRMS (ESI+TOF): calcd for C19H22NO ([MH+]), 280.1701; 
found, 280.1710. 
(4R)-1-(Phenylmethyl)-4-(4-methylphenyl)piperidin-2-one 13e 
Using glutarimide 4e (0.30 g, 1.00 mmol) the title compound 13e was obtained as a white solid 
using general procedure G (0.14 g, 54% over 2 steps, 92% ee determined by HPLC on a 
CHIRALPAK IA column (hexane/2-propanol = 92/7, flow rate = 1.0 mL/min, tminor = 31.3 min, 
tmajor = 32.9 min); mp = 105±106 oC; ሾȽሿୈଶ଴ +33.6 (c 1.1, CHCl3; 92% ee); Anal. Calcd for 
C19H21NO: C, 81.68; H, 7.58; N, 5.01. Found: C, 81.58; H, 7.54; N, 4.90; vmax / cm-1 (ATR) 2924 
(w, C-H), 1625 (s, C=O); įH (400 MHz, CDCl3) 1.89±1.99 (m, 1H), 2.05±2.12 (m, 1H), 2.36 (s, 
3H), 2.60 (dd, J = 17.5, 11.1 Hz, 1H), 2.83 (ddd, J = 17.5, 5.2, 2.0 Hz, 1H), 3.10 (tdd, J = 11.1, 
5.2, 3.1 Hz, 1H), 3.25±3.36 (m, 2H), 4.59 (d, J = 14.6 Hz, 1H), 4.76 (d, J = 14.6 Hz, 1H), 7.13 
[(AX)2, 2H], 7.17 [(AX)2, 2H], 7.28±7.39 (m, 5H); įC (100 MHz, CDCl3) 21.0 (CH3), 30.4 
(CH2), 38.3 (CH), 39.6 (CH2), 46.4 (CH2), 50.0 (CH2), 126.4 (2 × CH), 127.4 (CH), 128.2 (2 × 
CH), 128.6 (2 × CH), 129.4 (2 × CH), 136.4 (C), 137.2 (C), 140.5 (C) 169.4 (C); HRMS 
(ESI+TOF): calcd for C19H22NO ([MH+]), 280.1701; found, 280.1692. 
(4R)-1-(Phenylmethyl)-4-(1-naphthyl)piperidin-2-one 13f 
Using glutarimide 4f (0.33 g, 1.00 mmol) the title compound 13f was obtained as a white solid 
using general procedure G (0.06 g, 20% over 2 steps, 54% ee determined by HPLC on a 
CHIRALPAK IA column (hexane/2-propanol = 92/7, flow rate = 1.0 mL/min, tmajor = 41.3 min, 
tminor = 44.9 min); mp = 122±124 oC; ሾȽሿୈଶ଴ -13.3 (c 0.5, CHCl3; 54% ee); vmax / cm-1 (ATR) 2950 
(w, C-H), 1636 (s, C=O), 1624 (s, C=O); įH (400 MHz, CDCl3) 2.10±2.20 (m, 1H), 2.25±2.28 
(m, 1H), 2.74 (dd, J = 17.5, 10.1 Hz, 1H), 3.05 (dd, J = 17.5, 3.6 Hz, 1H), 3.10 (dt, J = 10.1, 4.7 
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Hz, 1H), 3.38±3.45 (m, 1H), 3.95±3.99 (m, 1H), 4.61 (d, J = 14.5 Hz, 1H), 4.84 (d, J = 14.5 Hz, 
1H(?7.41 (m, 6H), 7.44±7.57 (m, 3H), 7.78 (d, J = 8.2 Hz, 1H), 7.90 (dd, J = 7.7, 1.5 Hz, 
1H), 8.06 (d, J = 8.2 Hz, 1H); įC (100 MHz, CDCl3) 29.6 (CH2), 33.8 (CH), 39.3 (CH2), 46.2 
(CH2), 50.2 (CH2), 122.4 (CH), 122.7 (CH), 125.6 (CH), 125.7 (CH), 126.3 (CH), 127.4 (CH), 
127.5 (CH), 128.3 (2 × CH), 128.7 (2 × CH), 129.1 (CH), 131.0 (C), 134.0 (C), 137.1 (C), 138.9 
(C), 169.5 (C); HRMS (ESI+TOF): calcd for C22H22NO ([MH+]), 316.1701; found, 316.1689. 
(4R)-1-(Phenylmethyl)-4-methylpiperidin-2-one 13g 
Using general procedure G and glutarimide 4g (0.22 g, 1.00 mmol) a crude oily solid was 
obtained which was purified via flash column chromatography eluting with EtOAc : petroleum 
ether (40±60) : Et3N (2:8:0.05) to afford the title compound 13g as pale yellow oil (0.09 g, 46% 
over 2 steps, 90% ee determined by HPLC on a Lux 3P CELLULOSE-2 column (hexane/2-
propanol = 80/20, flow rate = 1.0 mL/min, tminor = 13.2 min, tmajor = 14.1 min); ሾȽሿୈଶ଴ + 46.6 (c 
3.3, CHCl3; 90% ee); vmax / cm-1 (ATR) 2953 (w, C-H), 1634 (s, C=O); įH (400 MHz, CDCl3) 
1.01 (d, J = 6.5 Hz, 3H), 1.39±1.47 (m, 1H(?1.85 (m, 1H), 1.90(?2.00 (m, 1H), 2.07 (dd, J = 
17.2, 10.7 Hz, 1H), 2.58 (ddd, J = 17.2, 4.9, 2.1 Hz, 1H(씀3m, 2H), 4.48 (d, J = 14.7 
Hz, 1H), 4.72 (d, J = 14.7 Hz, 1H), 7.24±7.34 (m, 5H); įC (100 MHz, CDCl3) 21.0 (CH3), 28.0 
(CH), 30.9 (CH2), 40.5 (CH2), 46.3 (CH2), 50.0 (CH2), 127.3 (CH), 128.0 (2 × CH), 128.6 (2 × 
CH), 137.3 (C), 169.7 (C); HRMS (ESI+TOF): calcd for C13H18NO ([MH+]), 204.1388; found, 
204.1394. 
(4R)-1-(Phenylmethyl)-4-isopropylpiperidin-2-one 13h 
Using general procedure G and glutarimide 4h (0.22 g, 1.00 mmol) a crude oily solid was 
obtained which was purified via flash column chromatography eluting with EtOAc : CH2Cl2 : 
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petroleum ether (40±60) (3:1:6) to afford the title compound 13h as yellow oil (0.09 g, 41% over 
2 steps, 86% ee determined by HPLC on a Lux 3P CELLULOSE-2 column (hexane/2-propanol 
= 95/5, flow rate = 1.0 mL/min, tminor = 47.1 min, tmajor = 49.0 min); ሾȽሿୈଶ଴ + 44.3 (c 1.9, CHCl3; 
86% ee); vmax / cm-1 (ATR) 2957 (m, C-H), 2871 (m, C-H), 1676 (m, C=O), 1638 (s, C=O); įH 
(400 MHz, CDCl3) 0.92 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 1.40±1.60 (m, 3H(?
1.90 (m, 1H), 2.17 (dd, J = 17.5, 11.6 Hz, 1H), 2.61 (ddd, J = 17.5, 4.9, 2.3 Hz, 1H), 3.15(?3.27 
(m, 2H), 4.53 (d, J = 14.6 Hz, 1H), 4.71 (d, J = 14.6 Hz, 1H), 7.25±7.36 (m, 5H); įC (100 MHz, 
CDCl3) 19.3 (CH3), 19.6 (CH3), 26.6 (CH2), 31.9 (CH), 36.3 (CH2), 39.4 (CH), 46.8 (CH2), 49.9 
(CH2), 127.3 (CH), 128.0 (2 × CH), 128.6 (2 × CH), 137.2 (C), 170.3 (C); HRMS (ESI+TOF): 
calcd for C15H22NO ([MH+]), 232.1701; found, 232.1709. 
(4R)-1-(Phenylmethyl)-4-tert-butylpiperidin-2-one 13i 
Using general procedure F and glutarimide 4i (0.26 g, 1.00 mmol) an oily solid was obtained 
which was purified via flash column chromatography eluting with EtOAc : CH2Cl2 : petroleum 
ether (40±60) (3:1:6) to afford the title compound 12i as yellow oil (0.11 g, 46% over 2 steps, 
87% ee determined by HPLC on a Lux 3P CELLULOSE-2 column (hexane/2-propanol = 95/5, 
flow rate = 1.0 mL/min, tminor = 11.3 min, tmajor = 12.4 min); ሾȽሿୈଶ଴ + 36.8 (c 1.4, CHCl3; 87% ee); 
vmax / cm-1 (ATR) 2957 (s, C-H), 2867 (s, C-H), 1636 (s, C=O); įH (400 MHz, CDCl3) 0.90 (s, 
9H), 1.40 (qd, J = 12.5, 5.5 Hz, 1H), 1.57 (tdd, J = 12.5, 4.8, 2.3 Hz, 1H(?1.90 (m, 1H), 
2.21 (dd, J = 17.3, 12.5 Hz, 1H), 2.59 (ddd, J = 17.3, 4.8, 2.3 Hz, 1H), 3.17 (td, J = 12.6, 4.8 Hz, 
1H), 3.26 (ddd, J = 12.6, 5.5, 2.3 Hz, 1H), 4.53 (d, J = 14.6 Hz, 1H), 4.71 (d, J = 14.6 Hz, 1H), 
7.26±7.36 (m, 5H); įC (100 MHz, CDCl3) 24.6 (CH2), 26.8 (3 × CH3), 32.0 (C), 34.3 (CH2), 43.2 
(CH), 47.1 (CH2), 49.9 (CH2), 127.3 (CH), 128.1 (2 × CH), 128.6 (2 × CH), 137.2 (C), 170.5 
(C); HRMS (ESI+TOF): calcd for C16H24NO ([MH+]), 246.1858; found, 246.1861.  
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